Pacira Pharmaceuticals, Inc.  
 
 
 
DISCLOSURE: REDACTED CLINICAL STUDY PROTOCOL AMENDMENT 1 
 
Title: A Phase 3, Randomized, Double -Blind, Multicenter, Active -Controlled Study to Evaluate the 
Efficacy, Safety, and Pharmacokinetics of EXPAREL Admixed with Bupivacaine HCl vs. Bupivacaine HCl Administered via Adductor Canal Block for Postsurgical Analgesia in  Subjects Undergoing Primary 
Unilateral Total Knee Arthroplasty  
Study ID: [REMOVED]  
Protocol Number: 402-C-335  
Clinical Study Protocol Amendment 1 , Approval Date: 2 2-Oct -2021 
 
Certain information within this protocol has been redacted (ie, specific content is masked irreversibly from view with a black bar) to protect either personally identifiable information or company confidential information.  
 This may include, but is not limited to, redaction of the following:  
 
â€¢ Named persons or organizations associated with the study.  
â€¢ Proprietary information, such as scales or coding systems which are considered confidential information under prior agreements with license holder.  
â€¢ Other information as needed to protect confidentiality of Pacira Pharmaceuticals, Inc. or partners, personal information, or to otherwise protect the integrity of the clinical study.  
 The information contained in the following document is the property of Pacira Pharmaceuticals, Inc.  and 
should not be shared or used for any purpose other than for which it was provided.  
3DFLUD3KDUPDFHXWLFDOV, QF &$GG XFWRU&DQDO%ORFN
(;3$5(/ÂŠ &OLQLFDO6WXG\3URWRFRO$PHQGPHQW
&21),'(17,$/ RI 2&7
 
&OLQLFDO6WXG\3URWRFRO
$PHQGPHQW
$3KDVH5DQGRPL]HG'RXEOH%OLQ G0XOWLFHQWHU$FWLYH&RQWUR OOHG6WXG\WR(YDOXDWH
WKH(IILFDF\6DIHW\D QG3KDUPDFRNLQHWLFVRI(;3$5(/$GPL[HGZ LWK%XSLYDFDLQH+&O
YV%XSLYDFDLQH+&O$GPLQLVWHUHG YLD$GGXFWRU&DQDO%ORFNIRU3 RVWVXUJLFDO$QDOJHVLDLQ
6XEMHFWV8QGHUJRLQJ3ULPDU\8QLODWHUDO7RWDO.QHH$UWKURSODVW\

3URWRFRO1R & 
(XGUD&71R
,1'1R 1RWDSSOLFDEOH

6WXG\3KDVH 3KDVH
6WXG\'UXJ (;3$5(/ÂŠEXSLYDFDLQHOLSRVRPHLQ MHFWDEOHVXVSHQVLRQ 
2ULJLQDO3URWRFRO'DWH 6HS 
$PHQGPHQW'DWH 2FW
6WXG\6LWHV 0XOWLFHQWHUVWXG\LQW KH8QLWHG6WDWHV 
6SRQVRU 3DFLUD3KDUPDFHXWLFDOV,QF
6\OYDQ:D\3DUVLSSDQ\1HZ-HUVH\86$
7HOHSKRQH 







&RQILGHQWLDOLW\6WDWHPHQW
7KHLQIRUPDWLRQFRQWDLQHGLQWKLVGRFXPHQWLVFRQILGHQWLDODQG WKHSURSHUW\RI3DFLUD3KDUPDFHXWLFDOV,QFD
ZKROO\RZQHGVXEVLGLDU\RI3DFLUD%LRVFLHQFHV,QF,WVKRXOG QRWEHUHSURGXFHGUHYHDOHGRUVHQWWRWKLUGSDUWLHV
RWKHUWKDQ,QVWLWXWLRQDO5HYLHZ% RDUGV,QGHSHQGHQW(WKLFV&RPPL WWHHVDQGWKH,QYHVWLJDWRUÂ¶VUHVHDUFKVXSSRUWVWDII
SDUWLFLSDWLQJLQWKHFRQGXFWRIWKHVWXG\ZLWKRXWWKHSULRUZUL WWHQDXWKRUL]DWLRQRI3DFLUD3KDUPDFHXWLFDOV,QF
CCI
3DFLUD3KDUPDFHXWLFDOV, QF &$G GXFWRU&DQDO%ORFN
(;3$5(/ÂŠ &OLQLFDO6WXG\3UR WRFRO$PHQGPHQW

  
&21),'(17,$/ RI 2&76,*1$785(3$*(


 



' D W H 



' D W H 



' D W H 



' D W H 

' D W H CCI
CCI
CCI
CCI
CCI
3DFLUD3KDUPDFHXWLFDOV, QF &$G GXFWRU&DQDO%ORFN
(;3$5(/ÂŠ &OLQLFDO6WXG\3UR WRFRO$PHQGPHQW

  
&21),'(17,$/ RI 2&76<1236,6
1DPHRI6SRQVRU&RPSDQ\
3DFLUD3KDUPDFHXWLFDOV,QF
6\OYDQ:D\
3DUVLSSDQ\1-86$
,QGLYLGXDO6WXG\7DEOH5HIHUULQJ
WR3DUWRIWKH'RVVLHU9ROXPH
3DJH
)RU1DWLRQDO$XWKRULW\8VH2QO\
1DPHRI)LQLVKHG3URGXFW
(;3$5(/ÂŠEXSLYDFDLQH
OLSRVRPHLQ MHFWDEOHVXVSHQVLRQ
1DPHRI$FWLYH,QJUHGLHQW%XSLYDFDLQHP
JP/
7LWOHRI6WXG\ $3KDVH5DQGRPL]HG'RXEOH% OLQG0XOWLFHQWHU$FWLYH&RQWU ROOHG6WXG\WR(YDOXDWHWKH
(IILFDF\6DIHW\DQG3KDUPDFRNLQHWLFVRI(;3$5(/$GPL[HGZLWK %XSLYDFDLQH+&OYV %XSLYDFDLQH+&O
$GPLQLVWHUHGYLD$GGXFWRU&DQDO%ORFNIRU3RVWVXUJLFDO$QDOJHVL DLQ6XEMHFWV8QGHUJRLQJ3ULPDU\
8QLODWHUDO7RWDO.QHH$UWKURSODVW\ 
3ULQFLSDO,QYHVWLJDWRUV 7REHGHWHUPLQHG
6WXG\&HQWHUV 0XOWLFHQWHUVWXG\LQWKH 8QLWHG6WDWHV86
3XEOLFDWLRQV5HIHUHQFH 1RQH
'DWH)LUVW6XEMHFW(QUROOHG7REHGHWHUPLQHG 3KDVHRI'HYHORSPHQW

2EMHFWLYHV
3ULPDU\2EMHFWLYH
7KHSULPDU\REMHFWLYHLVWRFRPSDUHWKHPDJQLWXGHRIWKHSRVWVX UJLFDODQDOJHVLFHIIHFWIROORZLQJDVLQJOHGRVH
RI(;3$5(/DGPL[HGZLWKEXSLYDFDLQHK\GURFKORULGH+&OYVEXS LYDFDLQH+&OZKHQDGPLQLVWHUHGYLDDQ
DGGXFWRUFDQDOEORFNLQVXEMHFWVXQGHUJRLQJSULPDU\XQLODWHUDO WRWDONQHHDUWKURSODVW\7.$
6HFRQGDU\2EMHFWLYHV
7KHVHFRQGDU\REMHFWLYHVDUHWR
&RPSDUHWKHWRWDOSRVWVXUJLFDORSLRLGFRQVXPSWLRQLQRUDOPRUS KLQHHTXLYDOHQWVIROORZLQJDVLQJOH
GRVHRI(;3$5(/DGPL[HGZLWKEXSL YDFDLQH+&OYVEXSLYDFDLQH+& O
&RPSDUHWKHWLPHWRILUVWRSLRLGFRQVXPSWLRQSRVWVXUJHU\IROO RZLQJDVLQJOHGRVHRI(;3$5(/
DGPL[HGZLWKEXSLYDFDLQH+& OYVEXSLYDFDLQH+&O
&KDUDFWHUL]HDQGFRPSDUHWKHPDJQLWXGHRIWKHGXUDWLRQRIVHQVR U\DQGPRWRUEORFNIROORZLQJDVLQJOH
GRVHRI(;3$5(/DGPL[HGZLWKEXSLYDFDLQH+&ODQGEXSLYDFDLQH+& O
$VVHVVWKHVDIHW\DQGSKDUPDFRNLQHWLF3.SURILOHRI(;3$5(/ DGPL[HGZLWKEXSLYDFDLQH+&ODQG
EXSLYDFDLQH+&O
0HWKRGRORJ\
7KLVLVD3KDVHPXOWLFHQWHUUDQGRPL]HGGRXEOHEOLQGDFWLY HFRQWUROOHGVWXG\LQDSSUR[LPDWHO\VXEMHFWV
XQGHUJRLQJSULPDU\XQLODWHUDO7.$XQGHUVSLQDODQHVWKHVLD7KH VWXG\ZLOOKDYHFRKRUWV%RWKFRKRUWVZLOO
HQUROOLQSDUDOOHO
&RKRUW3.3'(II LFDF\DQG6DIHW\
&RKRUWZLOOHQUROODSSUR[LPDWHO\VXEMHFWVVXEMHFWVSHU WUHDWPHQWDUPXQGHUJRLQJSULPDU\XQLODWHUDO
7.$XQGHUVSLQDODQHVWKHVLDWRREWDLQLQIRUPDWLRQRQ3.SURILOH SKDUPDFRG\QDPLFV3'HIILFDF\DQG
VDIHW\6XEMHFWVZLOOEHUDQGRPL ]HGWRUHFHLYHDQDGGXFWR UFDQDOEORFNZLWKDVLQJOHGRVHRIHLWKHUCCI
3DFLUD3KDUPDFHXWLFDOV, QF &$G GXFWRU&DQDO%ORFN
(;3$5(/ÂŠ &OLQLFDO6WXG\3UR WRFRO$PHQGPHQW

  
&21),'(17,$/ RI 2&71DPHRI6SRQVRU&RPSDQ\
3DFLUD3KDUPDFHXWLFDOV,QF
6\OYDQ:D\
3DUVLSSDQ\1-86$
,QGLYLGXDO6WXG\7DEOH5HIHUULQJ
WR3DUWRIWKH'RVVLHU
9ROXPH
3DJH)RU1DWLRQDO$XWKRULW\8VH2QO\
1DPHRI)LQLVKHG3URGXFW
(;3$5(/ÂŠEXSLYDFDLQH
OLSRVRPHLQ MHFWDEOHVXVSHQVLRQ
1DPHRI$FWLYH,QJUHGLHQW%XSLYDFDLQHP
JP/
(;3$5(/P/PJDGPL[HGZLWKP/EXSLYDFDLQH+&O PJRUP/ EXSLYDFDLQH
+&OPJPL[HGZLWKP/QRUPDOVDOLQH7KHWRWDOGRVHYROX PHZLOOEHFRQVLVWHQWP/IRUDOOVXEMHFWV
&RKRUW(IILFDF\DQG6DIHW\
&RKRUWZLOOHQUROODSSUR[LPDWH O\VXEMHFWVVXEMHFWVSH UWUHDWPHQWDUPXQGHUJRLQJSULPDU\XQLODWHUDO
7.$XQGHUVSLQDODQHVWKHVLDWR REWDLQLQIRUPDW LRQRQHIILFDF\D QGVDIHW\6XEMHFWVLQWKLVFRKRUWZLOOEH
UDQGRPL]HGWRUHFHLYHDQDG GXFWRUFDQDOEORFNZLWKDVLQJ OHGRVHRIHLWKHU(;3$5(/P/PJ
DGPL[HGZLWKP/EXSLYDFDLQH+&OPJRUP/E XSLYDFDLQH+&OPJPL[HGZLWK
P/QRUPDOVDOLQH7KHWRWDOGRVH YROXPHZLOOEHFRQVLVWHQW P/IRUDOOVXEMHFWV

$QDGDSWLYHVWXG\GHVLJQZLOOEHXVHGLQWKLVVWXG\$QLQWHULP DQDO\VLVWRHYDOXDWHWKHVDPSOHVL]HDVVXPSWLRQV
DQGHYDOXDWHIXWLOLW\ZLOORFFXUZ KHQDWRWDORIDSSUR[LPDWHO\ VXEMHFWVLQHDFKDUPFRPELQHGIURP
HLWKHU&RKRUWRU&RKRUWKDYHHQUROOHGDQGSURYLGHGFRPSOHWH DVVHVVPHQWGDWDIRUWKHSULPDU\HIILFDF\
RXWFRPH

2EWDLQLQJ,QIRUPHG&RQVHQW
3RWHQWLDOVXEMHFWVXQGHUJRLQJSULPDU\XQLODWHUDO7.$XQGHUVSLQ DODQHVWKHVLDZLOOEHDSSURDFKHGE\WKH
,QYHVWLJDWRUDQGRUWKHVWXG\VWDIIIRULQIRUPHGFRQVHQWXSWR GD\VEHIRUHWKHVXUJHU\6XEMHFWVPD\EH
FRQVHQWHGRQWKHGD\RIWKHVXUJHU\LIWKHFRQVHQWSURFHVVLV VWDUWHGHDUO\ZLWKDPSOHWLPHIRUWKHVXEMHFWWR
UHYLHZWKHLQIRUPHGFRQVHQWIRUP,&)DQGKDYHDOOTXHVWLRQVD QVZHUHGE\WKH,QYHVWLJDWRUVWXG\VWDIISULRU
WRSURYLGLQJLQIRUPHGFRQVHQW

6FUHHQLQJ
6XEMHFWVPD\EHVFUHHQHGXSWRGD\VSULRUWRGD\RIVXUJHU\ EXWHOLJLELOLW\PXVWEHUHFRQILUPHGRQWKHGD\
RIVXUJHU\SULRUWRUDQGRPL]DWLRQ 6FUHHQLQJSURFHGXUHVWKDWDUHVWDQGDUGRIFDUHDWWKHLQVWLWX WLRQPD\EH
FRPSOHWHGSULRUWRZULWWHQLQIRUPHGFRQVHQWDQGGRFXPHQWHGZLWK LQWKHGD\WLPHZLQGRZ
7KHIROORZLQJVFUHHQLQJSURFHGXU HVZLOOEHSHUIRUPHGDIWHUWKH ,&)LVVLJQHGLIQRWVWDQGDUGRIFDUHDVVHVV
HOLJLELOLW\UHFRUGPHGLFDOVXUJLFDOKLVWRU\UHFRUGSULRUDQG FRQFRPLWDQWPHGLFDWLRQV UHODWHGWRPHGLFDO
KLVWRU\UHFRUGGHPRJUDSKLFVDQGEDVHOLQHFKDUDFWHULVWLFVUHF RUGVXEMHFWKHLJKWDQGZHLJKWIRUERG\PDVV
LQGH[ %0, FDOFXODWLRQ DVVHVV FKURQLF RSLRLG XVH LQ WKH SDVW  GD\V DYHUDJH Â• RUDO PRUSKLQH
HTXLYDOHQWVGD\FRQGXFWXULQHSUHJQDQF\WHVWIRUZRPHQRIFKL OGEHDULQJSRWHQWLDOSHUIRUPOHDG(.*
UHFRUGVHULRXVDGYHUVHHYHQWV6$(VVWDUWLQJZKHQWKH,&)LVV LJQHGDQGUHFRUGPHGLFDWLRQVIRUWUHDWPHQWRI
6$(V

'D\RI6XUJHU\
2QWKHGD\RIVXUJHU\EHIRUHDGPLQLVWUDWLRQRIWKHEORFNVWXG \VWDIIZLOOUHYLHZWKH3DLQ5DWLQJ*XLGHZLWK
WKHVXEMHFWDQGWKHQUHFRUGWKHVXEMHFWÂ¶VUHVSRQVHVWRWKHIROO RZLQJSDLQDVVHVVPHQWVCCI
3DFLUD3KDUPDFHXWLFDOV, QF &$G GXFWRU&DQDO%ORFN
(;3$5(/ÂŠ &OLQLFDO6WXG\3UR WRFRO$PHQGPHQW

  
&21),'(17,$/ RI 2&71DPHRI6SRQVRU&RPSDQ\
3DFLUD3KDUPDFHXWLFDOV,QF
6\OYDQ:D\
3DUVLSSDQ\1-86$
,QGLYLGXDO6WXG\7DEOH5HIHUULQJ
WR3DUWRIWKH'RVVLHU
9ROXPH
3DJH)RU1DWLRQDO$XWKRULW\8VH2QO\
1DPHRI)LQLVKHG3URGXFW
(;3$5(/ÂŠEXSLYDFDLQH
OLSRVRPHLQ MHFWDEOHVXVSHQVLRQ
1DPHRI$FWLYH,QJUHGLHQW%XSLYDFDLQHP
JP/
x3DLQLQWHQVLW\VFRUHVXVLQJWKHQXPHULFUDWLQJVFDOH156PHD VXUHGDVÂ³2QDVFDOHIURPWR
ZKHUHHTXDOVQRSDLQDQGHTXDOVWKHZRUVWSRVVLEOHSDLQZ KDWZDVWKH ZRUVWSDLQLQ\RXU
RSHUDWLYHNQHHLQWKHODVWGD\V"Â´
x3DLQLQWHQVLW\VFRUHVXVLQJWKH156PHDVXUHGDVÂ³2QDVFDOHI URPWRZKHUHHTXDOVQRSDLQ
DQGHTXDOVWKHZRUVWSRVVLEOHSDLQZKDWZDVWKH DYHUDJHSDLQLQ\RXURSHUDWLYHNQHHLQWKHODVW
GD\V"Â´
,QDGGLWLRQWKHIROORZLQJSURFHGXUHVZLOOEHFRQGXFWHGFRQGXF WXULQHGUXJVFUHHQFRQGXFWXULQHSUHJQDQF\
WHVWIRUZRPHQRIFKLOGEHDULQJSRWHQWLDOP HDVXUHDQGUHFRUGYLWDOVLJQVWH PSHUDWXUHUHVWLQJKHDUWUDWH 
UHVSLUDWRU\UDWHR[\JHQVDWXUDWLRQDQGEORRGSUHVVXUHLQVXSL QHSRVLWLRQUHFRUGFKDQJHVWRFRQFRPLWDQW
PHGLFDWLRQVVLQFHVFUHHQLQJFRQILUPHOLJLELOLW\DQGUDQGRPL]H VXEMHFWDQGUHFRUG$(V6$(VDQGDQ\
WUHDWPHQWVIRUWKHHYHQWV
)RU&RKRUWRQO\WKHIROORZLQJDGGLWLRQDOSURFHGXUHVZLOOEH FRQGXFWHGREWDLQ3.VDPSOHVDQGFRQGXFW
VHQVRU\PRWRUIXQFWLRQDVVHVVPHQWV 6HQVRU\DQGPRWRUIXQFWLRQDVVHVVPHQWVZLOOEHFRQGXFWHGE\WUD LQHG
EOLQGHGVWXG\VWDII
7UHDWPHQW$UPV
2QWKHGD\RIVXUJHU\VXEMHFWVZLOOUHFHLYHXOWUDVRXQGJXLGHG DGGXFWRUFDQDOEORFNZLWKRQHRIWKHIROORZLQJ
WUHDWPHQWV
(;3$5(/DGPL[DUP VXEMHFWVUDQGRPL]HGWRWKLVWUHDWPHQWDUPZLOOUHFHLYHP/ PJ
(;3$5(/DGPL[HGZLWKP/ PJEXSLYDFDLQH+&O
%XSLYDFDLQH+&ODUP VXEMHFWVUDQGRPL]HGWRWKLVWUHDWPHQWDUPZLOOUHFHLYHP/ PJ
EXSLYDFDLQH+&OPL[HGZ LWKP/QRUPDOVDOLQH

%ORFN3URFHGXUH
6XEMHFWVPD\EHOLJKWO\VHGDWHGZ LWKWRPJRIPLGD]RODPLQW UDYHQRXVO\,9EHIRUHWKHQHUYHEORFN
SURFHGXUH 7KH VWXG\ GUXJ (;3$5(/ DGPL[HG ZLWKEXSLYDFDLQH +&O  RU EXSLYDFDLQH +&O ZLOO EH
DGPLQLVWHUHGXQGHUXOWUDVRXQGJXLGDQFHPLQÂ“PLQSULRUW RVXUJHU\$SHULSKHUDOQHUYHVWLPXODWRUZLOO
EHXVHGWRFRQILUPQHUYHVLQWKHDGGXFWRUFDQDOEHIRUHVWXG\GU XJDGPLQLVWUDWLRQ$F RQILUPDWRU\XOWUDVRXQG
YLGHRZLOOEHFDSWXUHGGXULQJWKHQHUYHEORFNSURFHGXUHGXULQJ K\GURGLVVHFWLRQE\VDOLQHLQMHFWLRQDQGVWXG\
GUXJDGPLQLVWUDWLRQZLWKQHHGOHLQSODFHWRHQVXUHDFFXUDWHE ORFNSODFHPHQW7KH,QYHVWLJDWRUZLOOSURYLGH
WKHYLGHRWRWKHVSRQVRUZLWKLQKRXUVIURPWKHHQGRIEORFN SURFHGXUHWKDW ZLOOEHUHYLHZHGE\DQ
LQGHSHQGHQWXOWUDVRXQGDGMXGLFD WLRQFRPPLWWHHWRHQVXUHDFFXUDF \RIVWXG\GUXJDGPLQLVWUDWLRQ2QO\WZR
XQEOLQGHGVWXG\GUXJDGPLQLVWUDWRUVDQHVWKHVLRORJLVWZLOOEH DVVLJQHGSHUVLWHWRSHUIRUPWKHEORFNSURFHGXUHV
XQOHVVDSSURYHGLQDGYDQFHLQZULWLQJE\WKH6SRQVRURQDFDVH E\FDVHEDVLV7KHGHVLJQDWHGVWXG\GUXJ
DGPLQLVWUDWRUVDQHVWKHVLRORJLVWZLOOQRWSDUWLFLSDWHLQDQ\R WKHUVWXG\UHODWHGDVVHVVPHQWVDIWHUUDQGRPL]DWLRQ
)RUDOOVWXG\DUPVWKH WRWDOYROXPHRIP/ZLOOEHDGPLQLVWH UHGDVWKHDGGXFWRUFDQDOEORFN

3UH2SHUDWLYH0HGLFDWLRQ
$OOHOLJLEOHVXEMHFWVZLOODOVRU HFHLYHWKHIROORZLQJPHGLFDWLR QZLWKLQKRXUVSULRUWRVXUJHU\CCI
3DFLUD3KDUPDFHXWLFDOV, QF &$G GXFWRU&DQDO%ORFN
(;3$5(/ÂŠ&OLQLFDO6WXG\3UR WRFRO$PHQGPHQW

&21),'(17,$/ RI 2&71DPHRI6SRQVRU&RPSDQ\
3DFLUD3KDUPDFHXWLFDOV,QF
6\OYDQ:D\
3DUVLSSDQ\1-86$,QGLYLGXDO6WXG\7DEOH5HIHUULQJ
WR3DUWRIWKH'RVVLHU
9ROXPH
3DJH)RU1DWLRQDO$XWKRULW\8VH2QO\
1DPHRI)LQLVKHG3URGXFW
(;3$5(/ÂŠEXSLYDFDLQH
OLSRVRPHLQ MHFWDEOHVXVSHQVLRQ
1DPHRI$FWLYH,QJUHGLHQW%XSLYDFDLQHP
JP/
x&HOHFR[LEPJRUDOO\32
1RJDEDSHQWLQRLGVDUHDOORZHGIRUSDLQFRQWUROSHUSURWRFRO
$OOVXEMHFWVLQERWK&RKRUW DQG&RKRUW ZLOOUHFHLYHDQLQILOW UDWLRQEHWZHHQWKHSRSOLWHDODUWHU\DQG
FDSVXOHRIWKHNQHH,3$&.XQGHUXOWUDVRXQGJXLGDQFHZLWKP /RIEXSLYDFDLQH+&O 
PJLPPHGLDWHO\IROORZLQJVWXG\GUXJDGPLQLVWUDWLRQVKRXOGEHG RQHZLWKWKHVDPHVHWXSIRUWKHQHUYH
EORFN
$QHVWKHVLDDQG,QWUDRSHUDWLYH0HGLFDWLRQ
$OOVXEMHFWVZLOOUHFHLYHVSLQDODQHVWKHVLD LPPHGLDWHO\SULRUWR VXUJHU\ ZLWKEXSLYDFDLQH+&OXSWR
PJ1RRWKHUPHGLFDWLRQLQFOXGLQJRSLRLGVVKRXOGEHPL[HGZL WKWKHEXSLYDFDLQHIRUVSLQDODQHVWKHVLD,I
WKHVSLQDOIDLOVRUFDQQRWEHF RPSOHWHGWKHV XEMHFWPD\UHFHLY HWRWDOLQWUDYHQRXVDQHVWKHVLD7,9$
1RGH[DPHWKDVRQH16$,'VRUNHWDPLQHZLOOEHSHUPLWWHG$OOVXEMHFWVZLOOUHFHLYHDGRVHRIPJRILQWUDYHQRXV,9 DFHWDPLQRSKHQDWWKHWLPHRIVXUJLFDOLQFLVLRQ
,QWUDYHQRXV,9)HQWDQ\OZLOOEHDOORZHGIRULQWUDRSHUDWLYHSDL QFRQWURO)HQWDQ\OGRVHQRWWRH[FHHGXJNJ
XQOHVVGHHPHGPHGLFDOO\QHFHVVDU\
)XUWKHUGHWDLOVRQSHUPLWWHGUHVW ULFWHG SHULRSHUDWLYHPHGLFDWLRQ VDUHLQFOXGHGLQSURWRFRO 6HFWLRQV  DQG

6WXG\6FKHPD
3RVWVXUJLFDO3DLQ0DQDJHPHQW
$OORSLRLGDQGRWKHUDQDOJHVLFVSDLQ PHGLFDWLRQVDGPLQLVWHUHG SRVWVXUJHU\WKURXJKKRVSLWDOGLVFKDUJH ZLOO
EHUHFRUGHG
CCI
3DFLUD3KDUPDFHXWLFDOV, QF &$G GXFWRU&DQDO%ORFN
(;3$5(/ÂŠ &OLQLFDO6WXG\3UR WRFRO$PHQGPHQW

  
&21),'(17,$/ RI 2&71DPHRI6SRQVRU&RPSDQ\
3DFLUD3KDUPDFHXWLFDOV,QF
6\OYDQ:D\
3DUVLSSDQ\1-86$
,QGLYLGXDO6WXG\7DEOH5HIHUULQJ
WR3DUWRIWKH'RVVLHU
9ROXPH
3DJH)RU1DWLRQDO$XWKRULW\8VH2QO\
1DPHRI)LQLVKHG3URGXFW
(;3$5(/ÂŠEXSLYDFDLQH
OLSRVRPHLQ MHFWDEOHVXVSHQVLRQ
1DPHRI$FWLYH,QJUHGLHQW%XSLYDFDLQHP
JP/
$OOVXEMHFWVZLOOUHFHLYHRQHSRVWRSHUDWLYHGRVHRIPJ,9 DFHWDPLQRSKHQDGPLQLVWHUHGDSSUR[LPDWHO\
KRXUVDIWHUWKHILUVWGRVHDSSUR[LPDWHO\KRXUVDIWHULQFLV LRQ7KHPD[LPXPWRWDOGRVHZLOOQRWH[FHHG
PJ1RDGGLWLRQDODFHW DPLQRSKHQLVSHUPLW WHGDIWHUWKHVH FRQG,9DFHWDPLQRSKHQGRVH

2[\FRGRQHZLOOEHDGPLQLVWHUHGRQDQDVQHHGHG351EDVLVIRU EUHDNWKURXJKSDLQWKURXJKKRXUVSRVW
VXUJHU\RSLRLGVVKRXOGQRWEHJLYHQRQDSUHGHWHUPLQHGVFKHGX OH,PPHGLDWHUHOHDVHRUDO32R[\FRGRQH
ZLOOEHDGPLQLVWHUHGLQDVWHSZLVHDSSURDFK
x,QLWLDOGRVHRIPJR[\FRGRQHPD\EHRIIHUHG
x,IWKHLQLWLDORSLRLGGRVHLVLQVXIILFLHQWIRUSDLQUHOLHIDQ DGGLWLRQDOPJR[\FRGRQHPD\EHRIIHUHG
XSWRDPD[LPXPRIPJWRWDOGRVH
x,IDVXEMHFWLVXQDEOHWRWROHUDWH32PHGLFDWLRQRUWKH32R[\ FRGRQHSDLQUHOLHILVLQVXIILFLHQW,9
PRUSKLQHLQLWLDWHGDWPJ RUK\GURPRUSKRQHLQLWLDWHGDW PJPD\EHDGPLQLVWHUHG
1R16$,'VRURWKHURSLRLGVLQFOXGLQJ7UDPDGRODUHDOORZHGIRUW KHEUHDNWKURXJKSDLQPDQDJHPHQW1R
$FHWDPLQRSKHQRWKHU WKDQWKHVFKHGXOHG, 9DFHWDPLQRSKHQVKRXO GEHXVHGIRUEUHDNWKURXJKSDLQ 
)RUVWXG\SXUSRVHVLWLVLPSRUWDQWWRVWDQGDUGL]HSDLQPDQDJHP HQWPRGDOLWLHVGXULQJWKHILUVWKRXUVSRVW
VXUJHU\7KHUHIRUHWKHVWXG\ VWDIIPXVWDGKHUHFORVHO\WRWKHWUHDWPHQWRSWLRQVDQGUHTXLUHP HQWVQRWHGLQWKH
SURWRFRO$IWHUKRXUVWKHDQDOJHVLFUHJLPHQPD\EHDGMXVWHG IRUHDFKVXEMHFWLQGLYLGXDOO\DVGHHPHG
DSSURSULDWHE\WKHSK\VLFLDQUHV SRQVLEOHIRUWKHSRVWVXUJLFDOF DUH
3RVWVXUJLFDO$VVHVVPHQWV
7KHSRVWVXUJLFDODVVHVVPHQWVDUH DVIROORZVUHFRUGSDLQLQWHQ VLW\VFRUHVXVLQJWKH1XPHULFDO5DWLQJ6FDOH
156VHH$SSHQGL[ 6HFWLRQ PHDVXUHGDVÂ³2QDVFDOHIURPWRZKHUHHTXDOVQRSDLQ DQG
HTXDOVWKHZRUVWSRVVLEOHSDLQKRZPXFKSDLQDUH\RXH[SHULHQF LQJLQ\RXURSHUDWLYHNQHH ULJKWQRZ "Â´IURP
WKHHQGRIVXUJHU\WRKRXUVSRVWVXUJHU\DWWKHGHVLJQDWHGW LPHSRLQWV$GGLWLRQDODVVHVVPHQWVLQFOXGHUHFRUG
SDLQLQWHQVLW\VFRUHVXVLQJWKH 156PHDVXUHGDVÂ³2QDVFDOHIUR PWRZKHUHHTXDOVQRSDLQDQGHTXDOV
WKHZRUVWSRVVLEOHSDLQZKDWZDVWKH ZRUVWSDLQLQ\RXURSHUDWLYHNQHHLQWKHODVWKRXUV"Â´DQGÂ³2QDV FDOH
IURPWRZKHUHHTXDOVQRSDLQDQGHTXDOVWKHZRUVWSR VVLEOHSDLQZKDWZDVWKH DYHUDJHSDLQLQ\RXU
RSHUDWLYHNQHHLQWKHODVWKRXUV"Â´DQGVXEMHFWVDWLVIDFWLRQ ZLWKSDLQPDQDJHPHQWXVLQJWKHVXEMHFW
VDWLVIDFWLRQTXHVWLRQQDLUHDWK
9LWDOVLJQVZLOOEHPHDVXUHGDQGUHFRUGHGDVIROORZV  
x8SRQDUULYDOLQWKH3RVWDQHVWKHVLD&DUH8QLW3$&8Â“PLQ  
x$W3$&8GLVFKDUJHÂ“PLQ  
x(YHU\KRXUVIURPWKHHQGRIVXUJHU\XQWLOKRXUVSRVWVXUJH U\KÂ“KKÂ“KKÂ“K
KÂ“KK Â“KKÂ“KKÂ“ KKÂ“KKÂ“K KÂ“KKÂ“K
KÂ“KKÂ“KKÂ“K KÂ“KKÂ“K DQGDWKRVSLWDOGLVFKDUJH  
x$GGLWLRQDOO\IRU&RKRUWVXEMHFWVKÂ“KKÂ“K DQGKÂ“K
$OHDG(.*ZLOOEHSHUIRUPHGDW
xKÂ“KKÂ“KK Â“KDQGKÂ“K  CCI
3DFLUD3KDUPDFHXWLFDOV, QF &$G GXFWRU&DQDO%ORFN
(;3$5(/ÂŠ &OLQLFDO6WXG\3UR WRFRO$PHQGPHQW

  
&21),'(17,$/ RI 2&71DPHRI6SRQVRU&RPSDQ\
3DFLUD3KDUPDFHXWLFDOV,QF
6\OYDQ:D\
3DUVLSSDQ\1-86$
,QGLYLGXDO6WXG\7DEOH5HIHUULQJ
WR3DUWRIWKH'RVVLHU
9ROXPH
3DJH)RU1DWLRQDO$XWKRULW\8VH2QO\
1DPHRI)LQLVKHG3URGXFW
(;3$5(/ÂŠEXSLYDFDLQH
OLSRVRPHLQ MHFWDEOHVXVSHQVLRQ
1DPHRI$FWLYH,QJUHGLHQW%XSLYDFDLQHP
JP/
x$GGLWLRQDOO\IRU&RKRUWVXEMHFWVKÂ“KKÂ“K DQGKÂ“K  
2WKHUSRVWVXUJLFDODVVHVVPHQWVLQFOXGHUHFRUGDGYHUVHHYHQWV $(V6$(VDQGFRQFRPLWDQWPHGLFDWLRQV
)RU&RKRUWRQO\DGGLWLRQDODVVHVVPHQWVLQFOXGHFROOHFWVFKH GXOHG3.EORRGVDPSOHVSHUIRUPVHQVRU\DQG
PRWRUIXQFWLRQDVVHVVPHQWV
3RVWRSHUDWLYHO\WKHVXEMHFWZLOOSURJUHVVWRIXOOZHLJKWEHDUL QJDVWROHUDWHGSHUWKHVXUJHRQÂ¶VVWDQGDUGRIFDUH
$ZDONHULVUHFRPPHQGHGIRUSK\VLFDOWKHUDS\XQWLOWKHIDOOULV NLVPLQLPL]HGDQGWKHVXEMHFWFDQWUDQVIHUDQG
DPEXODWHVDIHO\
,QFDVHDQ$(RIVSHFLDOLQWHUHVW$(6,RUVHULRXV$(6$(RF FXUVGXULQJWKHVWXG\LIWKHLQYHVWLJDWRURU
PHGLFDOPRQLWRUFRQVLGHUVWKDWWKHHYHQWPD\EHUHODWHGWRVWXG \WUHDWPHQWRUVXJJHVWVWKHSRVVLEOHRFFXUUHQFH
RIORFDODQHVWKHWLFV\VWHPLFWR[LFLW\/$67ZLWKRUZLWKRXWWK HQHHGIRUWUHDWPHQW>HJLQWUDOLSLGV@DQ
XQVFKHGXOHG3.EORRGVDPSOHOHDG(.*DQGYLWDOVLJQVPXVW EHFROOHFWHG1HXURORJLFDODVVHVVPHQWVZLOO
EHFRQGXFWHGDFFRUGLQJWRWKHVWXG\VLWHÂ¶VVWDQGDUGRIFDUHDW OHDVWRQFHGDLO\XQWLOUHVROXWLRQRIV\PSWRPV
+HDOWK&DUH)DFLOLW\'LVFKDUJH
6XEMHFWVLQ&RKRUWDQG&RKRUWZLOOEHGLVFKDUJHGDIWHUWKH FRPSOHWLRQRIWKHKDQGKDVVHVVPHQWV
UHVSHFWLYHO\
3RVWRSHUDWLYH'D\32'3KRQHFDOOIROORZXS
)RUWKHDVVHVVPHQWRI$(V6$(VDQGFRQFRPLWDQWPHGLFDWLRQXVH DILQDOIROORZXSSKRQHFDOOZLOOEHPDGH
RQ32'Â“GD\V
1XPEHURI6XEMHFWV3ODQQHG
$WRWDORIDSSUR[LPDWHO\VXEMHFWVXQGHUJRLQJSULPDU\XQLODW HUDO7.$ZLOOEHHQUROOHGLQWKHVWXG\
$SSUR[LPDWHO\VXEMHFWVDUHSODQQHGIRU&RKRUWDQGZLOOEH UDQGRPL]HGWRHLWKHUWKH(;3$5(/DGPL[
DUPRUEXSLYDFDLQH+&,DUP
$SSUR[LPDWHO\VXEMHFWVDUHSODQQHGIRU&RKRUWDQGZLOOEH UDQGRPL]HGWRHLWKHUWKH(;3$5(/
DGPL[DUPRUEXSLYDFDLQH+&,DUP
(OLJLELOLW\&ULWHULD

,QFOXVLRQ&ULWHULD
0DOHRUIHPDOHDJHVRUROGHUDWVFUHHQLQJ
,QGLFDWHGWRXQGHUJRSULPDU\XQLODWHUDOWRWDONQHHDUWKURSODVW\ XQGHUVSLQDODQHVWKHVLD
3ULPDU\LQGLFDWLRQIRU7.$LVGHJH QHUDWLYHRVWHRDUWKULWLVRIWK HNQHH
$PHULFDQ6RFLHW\RI$QHVWKHVLRORJLVWV$6$SK\VLFDOVWDWXV RUVHH$SSHQGL[ 6HFWLRQ 
$EOHWRSURYLGHLQIRUPHGFRQVHQWDGKHUHWRWKHVWXG\VFKHGXOH DQGFRPSOHWHDOOVWXG\DVVHVVPHQWV
%RG\0DVV,QGH[%0,Â•DQGNJP


CCI
3DFLUD3KDUPDFHXWLFDOV, QF &$G GXFWRU&DQDO%ORFN
(;3$5(/ÂŠ &OLQLFDO6WXG\3UR WRFRO$PHQGPHQW

  
&21),'(17,$/ RI 2&71DPHRI6SRQVRU&RPSDQ\
3DFLUD3KDUPDFHXWLFDOV,QF
6\OYDQ:D\
3DUVLSSDQ\1-86$
,QGLYLGXDO6WXG\7DEOH5HIHUULQJ
WR3DUWRIWKH'RVVLHU
9ROXPH
3DJH)RU1DWLRQDO$XWKRULW\8VH2QO\
1DPHRI)LQLVKHG3URGXFW
(;3$5(/ÂŠEXSLYDFDLQH
OLSRVRPHLQ MHFWDEOHVXVSHQVLRQ
1DPHRI$FWLYH,QJUHGLHQW%XSLYDFDLQHP
JP/
([FOXVLRQ&ULWHULD
$OOHUJ\K\SHUVHQVLWLYLW\LQWROHUDQFHRUFRQWUDLQGLFDWLRQWR DQ\RIWKHVWXG\PHGLFDWLRQVIRUZKLFKDQ
DOWHUQDWLYHLVQRWQDPHGLQWKHSURWRFROHJDPLGHW\SHORFD ODQHVWKHWLFVRSLRLGVEXSLYDFDLQH+&O
16$,'V
3ODQQHGFRQFXUUHQWVXUJLFDOSURFHGXUHHJELODWHUDO7.$
8QGHUJRLQJXQLFRPSDUWPHQWDO7.$RUUHYLVLRQ7.$
&RQFXUUHQWSDLQIXOSK\VLFDOF RQGLWLRQHJDUWKULWLVILEURP\ DOJLDFDQFHUWKDWPD\UHTXLUHDQDOJHVLF
WUHDWPHQWZLWK16$,'VRURSLRLGVLQWKHSRVWGRVLQJSHULRGIRU SDLQWKDWLVQRWVWULFWO\UHODWHGWRWKH
NQHHVXUJHU\DQGZKLFKLQWKH,QYHVWLJDWRUÂ¶VRSLQLRQPD\FRQI RXQGWKHSRVWGRVLQJDVVHVVPHQWV
,QDGHTXDWHVHQVRU\IXQFWLRQEHORZWKHNQHHDVDVVHVVHGE\WKH, QYHVWLJDWRU
+LVWRU\RIFRQWUDODWHUDO7.$ZLWKLQ\HDU
3UHYLRXVRSHQNQHHVXUJHU\RQWKHNQHHEHLQJFRQVLGHUHGIRU7.$ 3ULRUDUWKURVFRS\LVSHUPLWWHG
+LVWRU\RIVXVSHFWHGRUNQRZQDGGLFWLRQWRRUDEXVHRILOOLFL WGUXJVSUHVFULSWLRQPHGLFLQHVRU
DOFRKROZLWKLQWKHSDVW\HDUV
$GPLQLVWUDWLRQ RI DQ LQYHVWLJDWLRQDO GUXJ ZLWKLQ  GD\V RU  H OLPLQDWLRQ KDOIOLYHV RI VXFK
LQYHVWLJDWLRQDOGUXJZKLFKHYHULVORQJHUSULRUWRVWXG\GUXJ DGPLQLVWUDWLRQRUSODQQHGDGPLQLVWUDWLRQ
RIDQRWKHULQYHVWLJDWLRQDOSURGXFWRUSURFHGXUHGXULQJWKHVXEM HFWÂ¶VSDUWLFLSDWLRQLQWKLVVWXG\
3UHYLRXVSDUWLFLSDWLRQLQDQ(;3$5(/VWXG\
8QFRQWUROOHG DQ[LHW\ VFKL]RSKUHQLD RU RWKHU SV\FKLDWULF GLVRU GHU WKDW LQ WKH RSLQLRQ RI WKH
,QYHVWLJDWRUFRXOGLQWHUIHUHZLWKVWXG\DVVHVVPHQWVRUFRPSOLD QFH
&XUUHQWO\SUHJQDQWQXUVLQJRUSODQQLQJWREHFRPHSUHJQDQWGXU LQJWKHVWXG\
&OLQLFDOO\VLJQLILFDQWPHGLFDOGLVHDVHWKDWLQWKHRSLQLRQRI WKH,QYHVWLJDWRUZRXOGPDNHSDUWLFLSDWLRQ
LQDFOLQLFDOVWXG\LQDSSURSULDWH7KLVLQFOXGHVGLDEHWLFQHXUR SDWK\FRDJXODWLRQRUEOHHGLQJGLVRUGHUV
VHYHUHSHULSKHUDOYDVFXODUGLVHDV HUHQDOLQVXIILFLHQF\KHSDWL FG\VIXQFWLRQRURWKHUFRQGLWLRQVWKDW
ZRXOGFRQVWLWXWHDFRQWUDLQGLFDWLRQWRSDUWLFLSDWLRQLQWKHVWX G\
&XUUHQWO\RQDQHXURPRGXODWLQJDJHQWHJJDEDSHQWLQSUHJDED OLQ>/\ULFD@GXOR[HWLQH>&\PEDOWD@
HWF@
&XUUHQWXVHRIV\VWHPLFJOXFRFRUWLFRLGVZLWKLQGD\VRIUDQGR PL]DWLRQLQWKLVVWXG\
8VHRIGH[PHGHWRPLGLQH+&O3UHFHGH[ Â®RUFORQLGLQHZLWKLQGD\VRIVWXG\GUXJDGPLQLVWUDWLRQ
$Q\XVHRIPDULMXDQD>LQFOXGLQJ7HWUDK\GURFDQQDELQRO7+&DQG &DQQDELGLRO&%'@ZLWKLQGD\V
SULRUWRUDQGRPL]DWLRQRUSODQQHGXVHGXULQJWKHFRXUVHRIWKH VWXG\
&KURQLF RSLRLG XVH DYHUDJH Â• RUDO PRUSKLQH HTXLYDOHQWVGD\ ZLWKLQ  GD\V SULRU WR
UDQGRPL]DWLRQ

*LYHQWKH&29,'SDQGHPLFLIWKHUHLVDFRQFHUQDERXWDVXEM HFWÂ¶VUHFHQWRUSRWHQWLDOH[SRVXUHWR&29,'
RULIWKHVXEMHFWLVQRWPHGLFDOO\ILWFOHDUHGIRUVXUJHU\ GXHWRVXVSHFWHG&29,'LOOQHVVV\PSWRPVWKH
VXEMHFWPXVWEHH[FOXGHGSHU([FOXVLRQFULWHULRQCCI
3DFLUD3KDUPDFHXWLFDOV, QF &$G GXFWRU&DQDO%ORFN
(;3$5(/ÂŠ &OLQLFDO6WXG\3UR WRFRO$PHQGPHQW

  
&21),'(17,$/ RI 2&71DPHRI6SRQVRU&RPSDQ\
3DFLUD3KDUPDFHXWLFDOV,QF
6\OYDQ:D\
3DUVLSSDQ\1-86$
,QGLYLGXDO6WXG\7DEOH5HIHUULQJ
WR3DUWRIWKH'RVVLHU
9ROXPH
3DJH)RU1DWLRQDO$XWKRULW\8VH2QO\
1DPHRI)LQLVKHG3URGXFW
(;3$5(/ÂŠEXSLYDFDLQH
OLSRVRPHLQ MHFWDEOHVXVSHQVLRQ
1DPHRI$FWLYH,QJUHGLHQW%XSLYDFDLQHP
JP/
7HVW3URGXFW'RVH0RGHRI$GPLQLVWUDWLRQDQG/RW1XPEHU
1DPH(;3$5(/EXSLYDFDLQHOLSRVRPHLQMHFWDEOHVXVSHQVLRQ
$FWLYHLQJUHGLHQW%XSLYDFDLQHPJP/'RVDJH
x(;3$5(/DGPL[DUP VLQJOHDGPLQLVWUDWLRQRIP/PJ(;3$5(/DGPL[HGZLWK P/
PJEXSLYDFDLQH+&O
/RWQXPEHU7REHGHWHUPLQHG
0RGHRIDGPLQLVWUDWLRQ$GGXFWRUFDQDOEORFN
5HIHUHQFH3URGXFW'RVH0RGHRI$GPLQLVWUDWLRQDQG/RW1XPEHU 
1DPH%XSLYDFDLQH+&O
$FWLYHLQJUHGLHQW%XSLYDFDLQH+&O'RVDJH
x%XSLYDFDLQHDUP VLQJOHDGPLQLVWUDWLRQRIP/PJEXSLYDFDLQH+&OPL[ HGZLWKP/
QRUPDOVDOLQH 
/RWQXPEHU7REHGHWHUPLQHG0RGHRIDGPLQLVWUDWLRQ$GGXFWRUFDQDOEORFN
'XUDWLRQRI6XEMHFW3DUWLFLSDWLRQLQWKH6WXG\
3DUWLFLSDWLRQZLOOEHJLQXSRQVLJQLQJRIWKH,&)1RPRUHWKDQ GD\VVKRXOGSDVVEHWZHHQVLJQLQJWKH,&)
DQGVWXG\GUXJDGPLQLVWUDWLRQ6W XG\GUXJDGPLQLVWUDWLRQZLOOE HRQWKHVDPHGD\RIVXUJHU\$IROORZXS
SKRQHFDOOZLOORFFXURQ32'Â“GD\V7KHUHIRUHHDFKVXEM HFWPD\SDUWLFLSDWHLQWKHVWXG\IRUXSWRD
PD[LPXPRIGD\V
(IILFDF\$VVHVVPHQWV
x3DLQLQWHQVLW\VFRUHXVLQJWKH15 6DVÂ³2QDVFDOHIURPWR ZKHUHHTXDOVQRSDLQDQGHTXDOVWKH
ZRUVWSRVVLEOHSDLQKRZPXFKSDLQDUH\RXH[SHULHQFLQJLQ\RXU RSHUDWLYHNQHH ULJKWQRZ "Â´ZLOOEH
DVVHVVHGE\WKHVWXG\VWDII
R8SRQDUULYDOLQWKH3RVWDQHVWKHVLD&DUH8QLW3$&8Â“PLQ
R(YHU\PLQXWHVLQWKH3$&8Â“PLQ
R$W3$&8GLVFKDUJHÂ“PLQ
R(YHU\KRXUVIURPWKHHQGRIVXUJHU\XQWLOKRXUVSRVWVXUJH U\KÂ“KKÂ“K
KÂ“KKÂ“KKÂ“KKÂ“KKÂ“K KÂ“KKÂ“KKÂ“
KKÂ“KKÂ“KKÂ“ KKÂ“KKÂ“ KDQGKÂ“K
x$QXQVFKHGXOHGSDLQLQWHQVLW\VFRUHXVLQJ156DVÂ³2QDVFDOHIU RPWRZKHUHHTXDOVQRSDLQDQG
HTXDOVWKHZRUVWSRVVLEOHSDLQKRZPXFKSDLQDUH\RXH[SHUL HQFLQJLQ\RXURSHUDWLYHNQHH ULJKW
QRZ"Â´ZLOOEHREWDLQHGLPPHGLDWHO\SULRUWRDGPLQLVWUDWLRQRIDQ\ EUHDNWKURXJKSDLQPHGLFDWLRQXQWLO
KRXUVSRVWVXUJHU\CCI
3DFLUD3KDUPDFHXWLFDOV, QF &$G GXFWRU&DQDO%ORFN
(;3$5(/ÂŠ &OLQLFDO6WXG\3UR WRFRO$PHQGPHQW

  
&21),'(17,$/ RI 2&71DPHRI6SRQVRU&RPSDQ\
3DFLUD3KDUPDFHXWLFDOV,QF
6\OYDQ:D\
3DUVLSSDQ\1-86$
,QGLYLGXDO6WXG\7DEOH5HIHUULQJ
WR3DUWRIWKH'RVVLHU
9ROXPH
3DJH)RU1DWLRQDO$XWKRULW\8VH2QO\
1DPHRI)LQLVKHG3URGXFW
(;3$5(/ÂŠEXSLYDFDLQH
OLSRVRPHLQ MHFWDEOHVXVSHQVLRQ
1DPHRI$FWLYH,QJUHGLHQW%XSLYDFDLQHP
JP/
x3DLQLQWHQVLW\XVLQJWKH156DWÂ“KÂ“KÂ“K DQGÂ“KSRVWVXUJHU\PHDVXUHGDV
Â³2QDVFDOHIURPWRZKHUHHTXDOVQRSDLQDQGHTXDOV WKHZRUVWSRVVLEOHSDLQZKDWZDVWKH
ZRUVWSDLQLQ\RXURSHUDWLYHNQHHLQWKHODVWKRXUV"Â´
x3DLQLQWHQVLW\XVLQJWKH156DWÂ“KÂ“KÂ“K DQGÂ“KSRVWVXUJHU\PHDVXUHGDV
Â³2QDVFDOHIURPWRZKHUHHTXDOVQRSDLQDQGHTXDOV WKHZRUVWSRVVLEOHSDLQZKDWZDVWKH
DYHUDJHSDLQLQ\RXURSHUDWLYHNQHHLQWKHODVWKRXUV"Â´
6XEMHFWVZLOOEHLQVWUXFWHGWRIRFXVDOO156SDLQLQWHQVLW\UDW LQJVRQWKHRSHUDWLYHNQHHDQGQRRWKHU
ORFDWLRQVZKHUHWKH\PD\EHH[SHULHQFLQJSDLQ
,QDGGLWLRQVXEMHFWVDWLVIDFWLRQZLWKSDLQPDQDJHPHQWXVLQJ TXHVWLRQIURPWKH,QWHUQDWLRQDO3DLQ2XWFRPH
,32TXHVWLRQQDLUHZLOOEHUHFRUGHGDWKRXUVÂ“KSRVWVX UJHU\

(IILFDF\(QGSRLQWV
3ULPDU\(IILFDF\(QGSRLQW
x7KHDUHDXQGHUWKHFXUYH$8&RIWKH156SDLQLQWHQVLW\VFRUHV IURPWRKRXUVSRVWVXUJHU\

6HFRQGDU\(IILFDF\(QGSRLQWV
x7RWDOSRVWVXUJLFDORSLRLGFRQVXPSWLRQLQRUDOPRUSKLQHHTXLYDOH QWV20('IURPWRKRXUVSRVW
VXUJHU\
x7LPHWRILUVWRSLRLGFRQVXP SWLRQSRVWVXUJHU\
x:RUVWDQGDYHUDJH156SDLQLQWHQVLW\VFRUHVDWKKKD QGKIURPWKHHQGRIVXUJHU\

6DIHW\$VVHVVPHQWV
7KHIROORZLQJVDIHW\DVVHVVPHQWVZLOOEHFRQGXFWHGE\EOLQGHGV WXG\VWDIIDWWKHWLPHSRLQWVVSHFLILHG
x6$(VZLOOEHUHFRUGHGIURPWKHWLPHRILQIRUPHGFRQVHQWDQG$(V ZLOOEHUHFRUGHGIURPWKHWLPHRI
UDQGRPL]DWLRQWKURXJK32'
6DIHW\(QGSRLQW
x,QFLGHQFHRIWUHDWPHQWHPHUJHQW$(VDQG6$(VIURPWKHVWDUWRI WKHQHUYHEORFNSURFHGXUHWKURXJK
32'
3KDUPDFRNLQHWLFDQG3KDUPDFRG\QDPLF$VVHVVPHQWV&RKRUW6XEMH FWV2QO\
%ORRGVDPSOHVIRU3.DVVHVVPHQWDQGWKHVHQVRU\PRWRUIXQFWLRQ DVVHVVPHQWVZLOOEHDVVHVVHGDWVFKHGXOHG
WLPHSRLQWVLQ&RKRUWV XEMHFWVRQO\6HH 7DEOH

3KDUPDFRNLQHWLF(QGSRLQWV 7KHIROORZLQJ3.HQGSRLQWVZLOOEHGHWHUPLQHG 
x$UHDXQGHUWKHSODVPDFRQFHQWUDWLRQYHUVXVWLPHFXUYH$8&
x0D[LPXPSODVPDFRQFHQWUDWLRQ& PD[DQGWLPHRI& PD[7PD[
x7KHDSSDUHQWWHUPLQDOHOLPLQDWLRQKDOIOLIHW HO
x$SSDUHQWFOHDUDQFH&/)CCI
3DFLUD3KDUPDFHXWLFDOV, QF &$G GXFWRU&DQDO%ORFN
(;3$5(/ÂŠ &OLQLFDO6WXG\3UR WRFRO$PHQGPHQW

  
&21),'(17,$/ RI 2&71DPHRI6SRQVRU&RPSDQ\
3DFLUD3KDUPDFHXWLFDOV,QF
6\OYDQ:D\
3DUVLSSDQ\1-86$
,QGLYLGXDO6WXG\7DEOH5HIHUULQJ
WR3DUWRIWKH'RVVLHU
9ROXPH
3DJH)RU1DWLRQDO$XWKRULW\8VH2QO\
1DPHRI)LQLVKHG3URGXFW
(;3$5(/ÂŠEXSLYDFDLQH
OLSRVRPHLQ MHFWDEOHVXVSHQVLRQ
1DPHRI$FWLYH,QJUHGLHQW%XSLYDFDLQHP
JP/
x$SSDUHQWYROXPHRIGLVWULEXWLRQ9G
3KDUPDFRG\QDPLF(QGSRLQWV 7KHIROORZLQJSKDUPDFRG\QDPLFVHQGSRLQWVZLOOEHGHWHUPLQHG
x0HGLDQWLPHWRRQVHWRIVHQ VRU\EORFNDQGP RWRUEORFN
x0HGLDQGXUDWLRQRIVHQVRU \EORFNDQGPRWRUEORFN
6WDWLVWLFDO0HWKRGV
7KHWRWDOVDPSOHVL]HZDVFDOFXO DWHGEDVHGRQWKHSULPDU\RXWFR PHPHDVXUHRI156SDLQLQWHQVLW\VFRUHV$
WRWDOVDPSOHVL]HRIVXEMHFWVUDQGRPL]DWLRQ(;3$5( /DGPL[HGZLWKEXSLYDFDLQH+&O
%XSLYDFDLQH+&OSURYLGHVDWOHDVWSRZHUWRGHWHFWDWUHDWP HQWGLIIHUHQFHRIXQLWVLQWKH$8&V
6' FRPSDULQJ(;3$5(/DGPL[DUPZLWKEXSLYDFDLQH+&ODUPD WRQHVLGHGVLJQLILFDQFHOHYHO

$8&RI156SDLQLQWHQVLW\VFRUHVIURPKRXUVSRVWVXUJHU\Z LOOEHDQDO\]HGXVLQJWKH$QDO\VLVRI
&RYDULDQFH$1&29$PRGHO7KHPDLQFRQWUDVWRILQWHUHVWWRDVV HVVWUHDWPHQWHIIHFWZLOOEHWKHGLIIHUHQFH
EHWZHHQ(;3$5(/DGPL[DUPZLWKEXSLYDFDLQH+&ODUPLQWKH$8&R ISDLQVFRUHÂ¶V/HDVW6TXDUH0HDQV
7RWDOSRVWVXUJLFDORSLRLGFRQVXPSWLRQLQRUDOPRUSKLQHHTXLYDOH QWV20('IURPWRKRXUVZLOOEH
DQDO\]HGXVLQJWKH$1&29$PRGHO7LPHWRILUVWSRVWVXUJLFDORSL RLGPHGLFDWLRQZLOOEHDQDO\]HGXVLQJWKH
.DSODQ0HLHUVXUYLYDOPHWKRG:RUVWDQGDYHUDJH156SDLQLQWHQV LW\VFRUHVWKURXJKKKKDQGK
IURPWKHHQGRIVXUJHU\ZLOOEHVXPPDUL]HGE\WUHDWPHQWDUP

'HVFULSWLYHVWDWLVWLFVQXPEHURI VXEMHFWVPHDQ6'PHGLDQP LQLPXPDQGPD[LPXPZLOOEHSURYLGHGIRU
FRQWLQXRXVGDWD7DEXODWLRQVQXPEHUDQGSHUFHQWDJHRIVXEMHFWV E\FDWHJRU\ZLOOEHSURYLGHGIRUFDWHJRULFDO
GDWD6DIHW\DQDO\VHVZLOOEHV XPPDUL]HGGHVFULSWLYHO\E\WUHDW PHQWDUPV
$QLQWHULPDQDO\VLVWRHYDOXDWH WKHVDPSOHVL]HDVVXPSWLRQVDQG HYDOXDWHIXWLOLW\ZLOORFFXUZKHQDWRWDORI
DSSUR[LPDWHO\VXEMHFWVVXEMHFWVLQ(;3$5(/DGPL[DUPDQG VXEMHFWVLQEXSLYDFDLQH+&ODUP
FRPELQHGIURPHLWKHU&RKRUWRU&RKRUWKDYHHQUROOHGDQGSUR YLGHGFRPSOHWHDVVHVVPHQWGDWDIRUWKH
SULPDU\HIILFDF\RXWFRPHCCI
Pacira Pharmaceuticals, Inc.                                                                                        402-C- 335 (Adductor Canal Block)  
EXPARELÂ®       Clinical Study Protocol Amendment 1  
 
CONFIDENTIAL   13 of 68  22 OCT 2021  Table 1: Time  and Events Schedule of Study  Procedures (Screening through  POD  14) 
 
Screen
-ing 
Visit1 Day of 
Surgery 
(Prior to 
Surgery)  O
R PA
CU Time from End of Surgery (h)   
Health 
Care 
Facility  
Discharge3 POD 
14 
Call 
Â±3 
days  6 
Â±2 12 
Â±2 18 
Â±2 24 
Â±2 30 
Â±2 36 
Â±2 42 
Â±2 48 
Â±2 54 
Â±2 60 
Â±2 66 
Â±2 72 
Â±2 78 
Â±3 84 
Â±3 90 
Â±3 96 
 Â±3 120-
168 
Â±32 
Obtain ICF*  X                       
Assess/confirm  
eligibility*  X X4 
                   
  
Record medical/  
surgical history*5 X                     
  
Collect height/weight for 
BMI calculation*  X                     
  
Demographics and 
baseline  
characteristics*  X                     
  
Record prior and 
concomitant  
Medications5 X X4                    
  
Urine pregnancy test for 
WOCBP  X X4                      
Urine drug screen   X4                      
Perform 12-lead EKG6 X       X    X    X    X X   
Review Pain Rating Guide   X4                      
Record worst  and average  
pain (NRS) in the last 
30 days  X4                    
  
Randomize subject; 
prepare study drug   X                      
Record block start/  
end times7  X                      
Capture ultrasound video 
for the nerve block and 
send to Sponsor   X                    
  
Record IPACK start/end 
times   X                      
Record surgery start and 
end times  
   X                   
  
Pacira Pharmaceuticals, Inc.                                                                                        402-C- 335 (Adductor Canal Block)  
EXPARELÂ®       Clinical Study Protocol Amendment 1  
 
CONFIDENTIAL   14 of 68  22 OCT 2021   
Screen
-ing 
Visit1 Day of 
Surgery 
(Prior to 
Surgery)  O
R PA
CU Time from End of Surgery (h)   
Health 
Care 
Facility  
Discharge3 POD 
14 
Call 
Â±3 
days  6 
Â±2 12 
Â±2 18 
Â±2 24 
Â±2 30 
Â±2 36 
Â±2 42 
Â±2 48 
Â±2 54 
Â±2 60 
Â±2 66 
Â±2 72 
Â±2 78 
Â±3 84 
Â±3 90 
Â±3 96 
 Â±3 120-
168 
Â±32 
   
O
R PA
CU Time from End of Surgery (h)     
 Screen
-ing 
Visit1 Day of 
Surgery 
(Prior to 
Surgery)   6 
Â±2 12 
Â±2 18 
Â±2 24 
Â±2 30 
Â±2 36 
Â±2 42 
Â±2 48 
Â±2 54 
Â±2 60 
Â±2 66 
Â±2 72 
Â±2 78 
Â±3 84 
Â±3 90 
Â±3 96 
 Â±3 120-
168 
Â±32 Health 
Care 
Facility  
Dis-
charge3 POD 
14 call 
Â±3 
days 
Record intra -op 
medication  
administered    X 
                  
  
Record Pre -op and post -op 
scheduled analgesic 
medication8  X  
                  
  
Record PACU time in and out 
   X 
                 
  
Record  scheduled  NRS 
scores9,10    X X X X X X X X X X X X X X X X X  
  
Measure and record vital 
signs11  X4  X X X X X X X X X X X X X X X X X X X 
 
Record wors t and average  
NRS scores  (24- hour 
recall)9,10        X    X    X    X  
  
Record unscheduled  NRS 
immediately prior to 
breakthrough pain 
medication12                      
  
Record breakthrough pain medication
12                        
Record day and time of 
HCF admission and 
discharge   X                    
X  
Record A Es/SAEs13                        
Perform unscheduled 
neurological assessment14                        
Pacira Pharmaceuticals, Inc.                                                                                        402-C- 335 (Adductor Canal Block)  
EXPARELÂ®       Clinical Study Protocol Amendment 1  
 
CONFIDENTIAL   15 of 68  22 OCT 2021  Abbreviations: AE=adverse event; BMI=Body Mass Index; h=hour(s); HCF=health care facility; ICF=informed consent form; IPO=International Pain Outcome; min=minute(s); 
NRS=numeric rating scale; NSAID=nonsteroidal anti -inflammatory drug; OR=Operating Room; PACU=Post -Anesthesia Care Unit; POD=Post -operative Day; SAE=serious adverse 
event; WOCBP=women  of childbearing potential.  
*  No more than 45 days before scheduled surgery day  
1. Subjects may be screened on the same day as health care facility admission/surgery (with ample time for the informed consent process) or up to 45 days prior to surgery, but 
eligibility will be re-confirmed on the day of surgery prior to randomization. Screening procedures that are standard of care at the institution may be completed prior to written 
informed consent.   Any screening procedures that are not SOC must be completed after written informed consent is obtained.   
2. For Cohort 1 subjects only: A 12- lead EKG will be performed,  and vital sign s will be measured and recorded at additional time points: 120 (Â±3h), 144 (Â±3h), and at 168 (Â±3h).  
3.   Subjects in Cohort 1 and Cohort 2  will be discharged after 168  h and 96  h assessments,  respectively.  
4. Eligibility criteria, prior medication, u rine pregnancy test , and urine drug screen  to be assessed prior to randomization; review of Pain Rating Guide and worst and average pain 
scores over the previous 30 days to be assessed prior to study drug administration .  
5.   Relevant medical/surgical history within the last 5 years (including all ongoing history, regardless of start date) should be recorded, with the exception of history that is relevant 
to the TKA surgery, in which case all years should be recorded.  Prior medications taken within 30 days of randomization (including all ongoing medications, regardless of start 
date) will be recorded.  
6. A baseline 12 -lead E KG must be performed  at screening visit. A 12 -lead E KG must be performed  if a subject experiences an AESI or an SAE (see footnote 15)  
7. Block to be administered 90 min (Â±30 min) prior to surgery.  
8.  Record all pre- operative and post -operative scheduled analgesic medication (celecoxib and acetaminophen)  
9.   The NRS pain intensity assessment should not be completed  after any physical activity, including the motor block assessment  (for Cohort 1 subjects). If that is not possible, to 
assess pain intensity at rest, the subject should rest quietly in a supine or seated position that does not exacerbate subjectâ€™s postsur gical pain for 5 -10 minutes before assessing 
the pain score using the NRS .  If a subject is asleep, the subject will not be awakened to assess pain. If the subject awakens within the assessment window,  a pain score will be 
collected then . 
10. Pain scores ( 24 hr recall) once daily (i.e., worst/average pain) will be collected at  24 (Â±2 h), 48 (Â±2 h), 72 (Â±2 h), and 96 (Â±3 h) post -surgery . Pain scores (current pain) will be 
collected by the study staff beginning at PACU admission (Â±5 min); q15 min in PACU  (Â±5 min); at PACU discharge (Â±5 min) ; then q6h (Â±2 h) from end of surgery to 72 hours 
post-surgery and q6h (Â±3 h) from 78- 96 hours post -surgery.  
11. Vital signs ( temperature, resting heart rate, respiratory rate, oxygen saturation and blood pressure) will be measured after the subject has rested in a supine position for at least 5 
minutes.  Vital signs will be measured before study drug administration, upon arrival in the PACU (Â±5 min), at PACU discharge  (Â±5 min), then q6h (Â±2 h) from end of surgery 
to 72 ho urs post -surgery and q6h (Â±3 h) from 78-96 hours post -surgery, and at hospital discharge. Additionally, for Cohort 1 subjects: 120 h (Â±3 h), 144 h (Â±3 h), and 168 h (Â±3 
h). Vital signs must be measured and recorded if a subject experiences an AESI or an SA E (see footnote 15 ) 
12.  Oxycodone will be administered  on an as needed (PRN) basis  for breakthrough pain through 96 hours post -surgery;  opioids should not be given on a pre -determined schedule. 
Immediate release oral (PO) oxycodone will be administered in a stepwise approach:  
â€¢ Initial dose of 5 mg oxycodone may be offered.  
â€¢ If the initial opioid dose is insufficient for pain relief, an additional 5 mg oxycodone may be offered up to a maximum of 10 mg (total dose) .  
Screen
-ing 
Visit1 Day of 
Surgery 
(Prior to 
Surgery)  O
R PA
CU Time from End of Surgery (h)   
Health 
Care 
Facility  
Discharge3 POD 
14 
Call 
Â±3 
days  6 
Â±2 12 
Â±2 18 
Â±2 24 
Â±2 30 
Â±2 36 
Â±2 42 
Â±2 48 
Â±2 54 
Â±2 60 
Â±2 66 
Â±2 72 
Â±2 78 
Â±3 84 
Â±3 90 
Â±3 96 
 Â±3 120-
168 
Â±32 
Subject â€™s satisfaction 
questionnaire  (IPO)                     X    
Pacira Pharmaceuticals, Inc.                                                                                        402-C- 335 (Adductor Canal Block)  
EXPARELÂ®       Clinical Study Protocol Amendment 1  
 
CONFIDENTIAL   16 of 68  22 OCT 2021  If a subject is unable to tolerate PO medication (or the PO oxycodone pain relief is insufficient), IV morphine (initiated at 2 mg) or hydromorphone (init iated at 0.2 mg) may be 
administered.  
13. D ocument all AEs with an onset after the subject is randomized and SAEs with an onset after the subject signs the ICF . 
14. An unscheduled neurological assessment will be conducted once daily if a subject experiences an AESI or an SAE, until resolution  of symptoms (see footnote 15).  
15. In case an AE of special interest (AESI) or serious AE (SAE) occurs during the study, if the investigator or medical monitor considers that the event may be related to s tudy 
treatment or suggests the possible occurrence of local anesthetic systemic toxicity (LAST; with or without the need for treat ment [e.g., intralipids]), an unscheduled PK blood 
sample, 12 -lead EKG, and vital signs must be collected. Neurological assessments will be conducted according to the study siteâ€™s standard of care at least once daily until 
resolution of symptoms.   
Pacira Pharmaceuticals, Inc.                                                                                        402-C- 335 (Adductor Canal Block)  
EXPARELÂ®       Clinical Study Protocol Amendment 1  
 
CONFIDENTIAL   17 of 68  22 OCT 2021  Table 2: Pharmacokinetic and Pharmacodynamic Assessments ( Cohort 1 S ubjects only)  
  Post-study Drug Administrationa 
  Day of Study Drug Administration to Post -operative Day 4 (POD  4) POD  5 POD  6 POD  7 
Time Window  Up to 
15 mins 
before 
blocks  15m 30m 45m 1h 2h 8h 12h 24h 30h 48h 60h 72h 84h 96h 120h  144h  168h  
Â±5m  Â±5m  Â±5m  Â±15m  Â±30m  Â±30m  Â±30m  Â±1h Â±1h Â±1h Â±2h Â±2h Â±2h Â±3h Â±3h Â±3h Â±3h 
Collect PK blood 
sample; Record date and time of blood sample
b X  X X X X X X X X X X X X X X X X 
Assess and record sensory and 
motor function
c,d X X X X X X X X X X X X X X X X X X 
Abbreviations: h=hour; m=minute; PK=pharmacokinetic  
a. All timepoints are from end of block administration.  
b. An unscheduled PK sample must be collected if a subject experiences an AESI or an SAE (see footnote 15 in Table 1)  
c. Once the offset of light touch sensation is recorded and documented in both locations , no further scheduled sensory assessments are required.  Once the offset of motor block 
is recorded and documented, no further scheduled motor assessments are required. Pharmacodynamic assessments must be performed by blinded, trained, licensed medical 
staff (e.g., Physician, Registered Nurse, Physician Assistant) and document ed on the investigatorâ€™s study delegation log. A limited number of study staff should perform the 
sensory/motor assessments.   
d. When subject is in surgery, no sensory or motor function  assessments will be conducted.
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  18 of 68 22 OCT 2021  3.  TABLE OF CONTENTS  
1. SIGNATURE PAGE  ........................................................................................................... 2  
2. SYNOPSIS  .......................................................................................................................... 3  
3. TABLE OF CONTENTS  .................................................................................................. 18  
4. LIST OF ACRONYMS/ABBREVIATIONS AND DEFINITIONS OF TERMS  ........... 22  
4.1. List of Acronyms/Abbreviations ................................................................................ 22  
4.2. Definition of Terms  .................................................................................................... 23  
5. ETHICS  ............................................................................................................................. 24  
5.1. Institutional Review Board/Independent ethics committee  ....................................... 24  
5.2. Ethical Conduct of the Study ..................................................................................... 24  
5.3. Subject Information, and Consent .............................................................................. 24  
6. INVESTIGATORS AND STUDY ADMINISTRATION STRUCTURE  ....................... 24  
7. INTRODUCTION  ............................................................................................................. 24  
7.1. Indication .................................................................................................................... 25  
7.2. Current Therapies/Treatments  .................................................................................... 25  
7.3. EXPAREL (Bupivacaine Liposome Injectable Suspension) ..................................... 26  
7.4. Summary of Human Clinical Experience with EXPAREL  ....................................... 26  
7.5. Rationale of the Study ................................................................................................ 27  
8. OBJECTIVES  ................................................................................................................... 27  
8.1. Primary Objective  ...................................................................................................... 27  
8.2. Secondary Objectives  ................................................................................................. 27  
9. OVERALL STUDY DESIGN AND PLAN  ..................................................................... 28  
9.1. Study Design .............................................................................................................. 28  
9.2. Duration of the Study and Subject Participation ........................................................ 29  
9.2.1  Study Stopping Rules  ..................................................................................... 29  
9.3. Discussion of Study Design ....................................................................................... 30  
10. STUDY POPULATION  .................................................................................................... 30  
10.1.  Inclusion Criteria  ............................................................................................ 30  
10.2.  Exclusion Criteria  ........................................................................................... 30  
10.3.  Removal of Subjects from Therapy or Assessment ....................................... 32  
10.3.1.  Withdrawal Secondary to Adverse Events .............................................. 32  
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  19 of 68 22 OCT 2021  10.3.2.  Voluntary or Study Investigator Withdrawal .......................................... 32  
10.3.3.  Early Termination Assessments  .............................................................. 33  
11. TREATMENTS  ................................................................................................................. 33  
11.1.  Treatments to be Administered  ...................................................................... 33  
11.1.1.  Study Drug Administration Considerations ............................................ 34  
11.1.2.  Bupivacaine HCl Administration Considerations ................................... 34  
11.2.  Identity of Investigational Products ............................................................... 34  
11.2.1.  Description of EXPAREL ....................................................................... 34  
11.2.2.  Description of Reference Product  ........................................................... 34  
11.2.3.  Description of Volume Expansion Agent ............................................... 35  
11.3.  Method of Assigning Subjects to Treatment .................................................. 35  
11.3.1.  Randomization Scheme .......................................................................... 35  
11.3.2.  Randomization Procedures for Treatment Assignment .......................... 35  
11.3.3.  Replacement of Subjects  ......................................................................... 35  
11.4.  Selection of Doses in the Study ..................................................................... 35  
11.5.  Blinding .......................................................................................................... 36  
11.5.1.  Blinding Procedures ................................................................................ 36  
11.5.2.  Unblinding Procedure ............................................................................. 36  
11.6.  Prior and Concomitant Therapy and Medications ......................................... 37  
11.6.1.  Before S tudy Drug Administration ......................................................... 37  
11.6.2.  Perioperative  ........................................................................................... 38  
11.6.3.  Post- Surgery  ............................................................................................ 38  
11.7.  Postsurgical Pain Medication for Breakthrough Pain .................................... 39  
11.8.  Treatment Compliance  ................................................................................... 39  
11.9.  Accountability of Study Drug ........................................................................ 39  
12. STUDY ENDPOINTS AND MEASUREMENTS  ........................................................... 40  
12.1.  Efficacy Assessments  ..................................................................................... 40  
12.2.  Efficacy Endpoints ......................................................................................... 40  
12.3.  Safety Assessments  ........................................................................................ 41  
12.4.  Safety Endpoints ............................................................................................ 41  
12.5.  Pharmacokinetic Assessments (Cohort 1 only) .............................................. 41  
12.6.  Pharmacokinetic Endpoints (Cohort 1 only) .................................................. 41  
12.7.  Pharmacodynamic Assessments (Cohort 1 only) ........................................... 41  
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  20 of 68 22 OCT 2021  12.8.  Pharmacodynamic Endpoints (Cohort 1 only) ............................................... 43  
12.9.  Appropriateness of Measures  ......................................................................... 43  
13. STUDY PROCEDURES  ................................................................................................... 43  
13.1.  Instructions for Conducting Procedures and Measures .................................. 43  
13.1.1.  Pain Intensity Assessment  ....................................................................... 43  
13.1.2.  Subject Satisfaction with Postsurgical Pain Control ............................... 44  
13.1.3.  Pharmacokinetic Assessments (Cohort 1 only) ...................................... 44  
13.1.4.  Pharmacodynamic Assessments (Cohort 1 only) ................................... 45  
13.2.  Study Procedures ............................................................................................ 45  
13.2.1.  Obtaining Informed Consent ................................................................... 45  
13.2.2.  Screening  ................................................................................................. 45  
13.2.3.  Baseline Procedures (Prior to Study Drug Administration) ................... 46  
13.3.  Nerve Block Procedure  .................................................................................. 46  
13.3.1  Procedures for Adductor Canal Block .................................................... 47  
13.4.  IPACK Infiltration Procedure ........................................................................ 48  
13.5.  Post-Block Assessments and Procedures ....................................................... 49  
13.6.  Intraoperative Procedures ............................................................................... 49  
13.7.  Post- Anesthesia Care Unit (PACU) Procedures  ............................................ 50  
13.8.  Postsurgical Assessments from End of Surgery through Discharge .............. 50  
13.9.  Health Care Facility Discharge  ...................................................................... 51  
13.10.  Unscheduled Visits ......................................................................................... 51  
13.11.  Postsurgical Day 14 Follow-up Phone Call ................................................... 52  
14. ADVERSE EVENT REPORTING  ................................................................................... 52  
14.1.  Adverse Events  ............................................................................................... 52  
14.1.1.  Definitions  ............................................................................................... 52  
14.1.2.  Recording Adverse Events ...................................................................... 52  
14.1.3.  Severity of Adverse Events ..................................................................... 53  
14.1.4.  Relationship of Adverse Events to Study Drug ...................................... 53  
14.1.5.  Outcome of Adverse Events ................................................................... 54  
14.1.6.  Action Taken with Subject Due to an Adverse Event ............................ 54  
14.1.7.  Adverse Events of Special Interest  ......................................................... 55  
14.2.  Serious Adverse Events .................................................................................. 56  
14.2.1.  Definition of a Serious Adverse Event ................................................... 56  
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  21 of 68 22 OCT 2021  14.2.2.  Reporting Serious Adverse Events ......................................................... 56  
15. STATISTICAL METHODS  ............................................................................................. 57  
15.1.  Study Hypothesis ........................................................................................... 57  
15.2.  Study Endpoints ............................................................................................. 57  
15.3.  Determination of Sample Size  ....................................................................... 57  
15.4.  Analysis Populations ...................................................................................... 57  
15.5.  Handling Subject Dropouts and Discontinuations ......................................... 58  
15.6.  Statistical Analyses  ........................................................................................ 58  
15.6.1.  Baseline Characteristics  .......................................................................... 58  
15.6.2.  Efficacy Analyses  ................................................................................... 58  
15.6.3.  Safety Analyses  ....................................................................................... 58  
15.6.4.  Pharmacokinetic Analysis  ....................................................................... 59  
15.7.  Significance Testing  ....................................................................................... 59  
15.8.  Interim Analysis  ............................................................................................. 59  
16. REFERENCES  .................................................................................................................. 60  
17. INVESTIGATOR AGREEMENT  .................................................................................... 61  
18. APPENDICES  ................................................................................................................... 62  
18.1.  Appendix 1: Pain Intensity Scores using the Numeric Rating Scale (NRS) .. 63  
18.2.  Appendix 2: Subjectâ€™s Satisfaction with Pain Management Questionnaire ... 64  
18.3.  Appendix 3: Sensory Function Assessment (Light Touch assessment) (Cohort 
1 Subjects) ...................................................................................................... 65  
18.4.  Appendix 4: Motor Function Assessment (Cohort 1 Subjects) ..................... 67  
18.5.  Appendix 5: ASA Physical Status Classification System .............................. 68  
 
LIST OF TABLES  
Table 1: Time  and Events Schedule of  Study Procedures (Screening through POD 14) .............. 13  
Table 2:  Pharmacokinetic and Pharmacodynamic Assessments (Cohort 1 subjects 
only) ........................................................................................................................... 17  
 
LIST OF FIGU RES 
Figure 1:  Study Schema ............................................................................................................. 29  
 
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  22 of 68 22 OCT 2021  4. LIST OF ACRONYMS/ABBREVIATIONS AND DEFINITIONS OF 
TERMS 
4.1. List of Acronyms/Abbreviations 
AE Adverse event  
ANCOVA  Analysis of Covariance 
ASA American Society of Anesthesiology 
AUC  Area under the curve  
BMI  Body mass index  
CBD  Cannabidiol  
C/L Apparent clearance  
Cmax Maximum plasma concentration  
CFR Code of Federal Regulations 
CNS  Central nervous system  
CRF  Case Report Form  
eCRF  Electronic case report form  
FDA Food and Drug Administration 
GCP  Good Clinical Practice  
h Hour(s) 
HCF  
HCl Health care facility  
Hydrochloride 
ICF Informed consent form  
ICH International Conference on Harmonisation 
IEC Independent Ethics Committee  
IPACK  Infiltration between the Popliteal Artery and Capsule of the Knee 
IPO International Pain Outcome 
IRB Institutional Review Board  
IV Intravenous 
JCAHO Joint Commission on Accreditation of Healthcare Organizations  
LAST Local anesthetic system toxicity  
MedDRA Medical Dictionary for Regulatory Activities 
NDA  New Drug Application 
NRS  Numeric Rating Scale  
NSAIDs Non-steroidal anti -inflammatory drugs 
NVM  Nerve to Vastus Medialis  
OMED Oral morphine equivalent  
OR Operating room 
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  23 of 68 22 OCT 2021  PACU  Post Anesthesia Care Unit  
PNS Peripheral nerve stimulator  
POD Post-operative day 
PD 
PK Pharmaco dynamic (s) 
Pharmaco kinetic (s) 
SAE  Serious adverse event  
SAP Statistical analysis plan  
SD Standard d eviation  
t1/2el Apparent terminal elimination half -life 
TEAE 
THC  
TKA Treatment -emergent adverse event  
Tetrahydrocannabinol  
Total knee arthroplasty 
US United States  
Vd Apparent volume of distribution 
 
4.2. Definition of Terms 
Pharmacokinetic terms are defined in  Section 12.6. 
  
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  24 of 68 22 OCT 2021  5. ETHICS 
5.1. Institutional Review Board/Independent ethics committee  
Prior to enrolling subjects into this study, each study site will obtain the approval of an Institutional 
Review Board (IRB)/Independent Ethics Committee (IEC) that complies with the International 
Conference on Harmonisation (ICH) Good Clinical Practices (GCP) and/or the United States (US) 
Food and Drug Administration (FDA) Title 21 Code of Federal  Regulations (CFR) Part 56.  
Attention is directed to the basic elements that are required to be incorporated into the informed consent form (ICF) under 21 CFR Part 50.25 and ICH GCP. 
5.2. Ethical Conduct of the Study  
This study will be conducted in accordance with the clinical research guidelines established by the FDA Title 21 CFR, Parts 50, 54, 56, and 312, and the ICH GCP. Study documents will be maintained in accordance with applicable regulations. 
5.3. Subject Information, and Consent  
Before a subject undergoes any study- specific screening procedures, the Investigator or designee 
will thoroughly explain to the subject the purpose of the study, the associated procedures, and any expected effects and potential adverse reactions. A copy of the IRB-approved ICF will be provided 
to the subject, who will be given sufficient time and opportunity to inquire about the details of the study and decide whether or not to participate. The subject, and the study staff with whom he or she discusses the ICF, will sign and date the ICF. A photocopy of the signed ICF will be given to the subject.  
The Investigator will explain to the subject that he or she is completely free to decline entry into 
the study and may withdraw from the study at any time, for any reason, without risking his or her 
medical care. Similarly, the Investigator and/or Pacira Pharmaceuticals, Inc. (â€œPaciraâ€) will be free 
to withdraw the subject at any time for safety or administrative reasons. Any other requirements 
necessary for the protecti on of the human rights of the subject will also be explained, according to 
the current ICH GCP (E6) and the Declaration of Helsinki (1964, and as amended through 2000 [Edinburgh]).  
6. INVESTIGATORS AND STUDY ADMINISTRATION STRUCTURE  
Information regarding the investigators, sites, laboratories, and other service providers is available upon request to the IRBs and regulatory agencies. 
7. INTRODUCTION 
Postsurgical pain is one of the most common forms of acute pain ( Schug 1993; Carr 1999) .  
In contrast to chronic pain, for which no adaptive value has been demonstrated, acute pain is the 
normal physiological response to tissue insult or injury and has adaptive value by serving as a 
warning of danger or dama ge.  Most acute pain is either treatable or avoidable, especially when it 
occurs in a clinical setting.  However, if acute pain is poorly or inappropriately treated, it may 
progress to chronic pain  (Perkins 2000; Petersen -Felix 2002) .  Thus, effectively modulating the 
response to acute pain may be considered a primary step in the prevention of chronic pain (Stephen 
2003) .  The suboptimal management of acute pain has been recognized as a problem by clinicians 
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  25 of 68 22 OCT 2021  for more than 50 years (Papper 1952; Marks 1973)  and has been formally identified as a public 
health concern by various societies and government institutions worldwide.   
In 1992, the US Agency for Health Care Policy and Research developed guidelines for the 
management of postoperative pain in the hopes of increasing awareness of the consequences of 
poor pain control in the postoperative setting and promoting better pain management techniques 
(Stephen 2003) .  These consequences, which include delayed healing, longer hospitalization, and 
the development of chronic pain, are significant not only from the patientâ€™s perspective (decrease 
in functionality and quality of life) but also from the health economic perspective (increase in 
healthcare resource utilization and costs).   
A multimodal approach to postoperative analgesia, using a combination of agents ( e.g., opioids, 
local anesthetics, non -steroidal anti- inflammatory drugs [NSAIDs]), and delivery techniques 
(patient -controlled analgesia, epidural and regional blocks) is currently recognized as best practice 
for pain management  (Breivik 1995a; Breivik 1995b; American Society of Anesthesiologists 
[ASA] Task Force 1995; Dahl 2000) .  
EXPARELÂ® was developed to extend pain relief with a single -dose administration without the use 
of indwelling catheters and to decrease the requirement for supplemental opioid medications.  A 
New Drug Application (NDA) for EXPAREL was submitted as a 505(b)(2) application and subsequently approved by the US FDA on October 28, 2011 (NDA 022-496). On 2018, the FDA 
approved EXAPREL for interscalene brachial plexus nerve block for adults. On Mar ch 22, 2021, 
FDA approved EXPAREL use in patients 6 years of age and older for single -dose infiltration to 
produce postsurgical local analgesia.  
7.1. Indication  
EXPAREL was initially approved by the US FDA in 2011 for single -dose administration into the 
surgic al site to produce postsurgical analgesia.  The indication was amended and approved by the 
US FDA in 2018 to read: â€œEXPAREL is indicated for single -dose infiltration in adults to produce 
postsurgical local analgesia and as an interscalene brachial plexus b lock to produce postsurgical 
regional analgesia.  Safety and efficacy have not been established in other nerve blocks .â€   
The indication was further amended and approved by the US FDA in March 2021 to read: â€œEXPAREL is indicated:  
â€¢ In patients aged 6 years and older for single -dose infiltration to produce postsurgical local 
analgesia  
â€¢ In adults as an interscalene brachial plexus nerve block to produce postsurgical  regional 
analgesia.â€ 
7.2. Current Therapies/Treatments  
Effective postsurgical pain control is a  critical element in patient recovery following surgery, as  the 
majority of patients may experience significant pain, particularly in the first few days.  Improved postsurgical pain management contributes to better healing, faster patient mobilization, shortened hospital stays, and reduced healthcare costs  (ASA Task Force 1995) . 
Current modalities of postsurgical analgesic treatment include infiltration and nerve block with 
local anesthetic agen ts, usually combined with the systemic administration of analgesics 
(multimodal therapy).  Multimodal therapy usually includes opioid medications, NSAIDs, and/or 
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  26 of 68 22 OCT 2021  acetaminophen provided through a variety of routes including intravenous, transdermal patch, a nd 
oral administration.  Opioids are widely used and considered amongst the most powerful analgesics; 
however, they also have considerable drawbacks , including time and resources required for 
monitoring opioid- related side effects.  A  reduction in the use of postoperative opioids is desirable 
to decrease the incidence and severity of opioid -induced adverse effects, such as respiratory 
depression, nausea, vomiting, constipation, somnolence, pruritus, and urinary retention.   
Postoperative pain is a predictab le component of the postoperative process, which  is often poorly 
managed, resulting in clinical and physiological changes that increase morbidity and mortality 
(inability to ambulate early, etc.), diminish quality of life, and extend length of stay, thereby 
increasing hospital expenditures (Oderda 2007)  and reducing patient satisfaction.  Effective relief 
of acute pain with minimal opioid complications, on the other hand, may improve clinical outcomes, avoid complications (like delay in regaining bowel function or an inability to tolerate liquid and solid oral intake), and conserve healthcare resources.  As  such, the Joint Commission on 
Accreditation of Healthcare Organizations ( JCAHO) requires that all healthcare facilities practice 
adequate pain management and monitor opioid- related adverse events (A Es) (Apfelbaum 2003) . 
7.3. EXPAREL ( Bupivacaine Liposome Injectable Suspension)  
Bupivacaine is one of the longer -acting local anesthetics, but even so it has a limited duration 
of action after local ad ministration, usually less than 8 hours.  EXPAREL  (Pacira Pharmaceuticals, 
Inc., [â€œPaciraâ€])  is a bupivacaine liposome injectable suspension.  It  consists of microscopic 
spherical, multivesicular liposomes (DepoFoamÂ® drug delivery system), organized in a 
honeycomb- like structure comprising numerous non- concentric internal aqueous chambers 
containing a bupivacaine base at a concentration of 13.3 mg/mL.  Each chamber is separated from 
adjacent chambers by lipid membranes.  The  lipids (phospholipids, cholesterol, and triglycerides) 
are naturally occurring or close analogs of endogenous lipids.  Bupivacaine is slowly released from 
the DepoFoam particles by a complex mechanism involving reorganization of the barrier lipid membranes and subsequent diffusion of the drug over an extended period of time.   
EXPAREL was approved by the US FDA in 2011 for administration into the surgical site to produce 
postsurgical analgesia. The active ingredient (bupivacaine) and inactive ingredient (DepoFoam) of EXPAREL are each contained, though separately, in FDA-approved products. 
â€¢ Bupivacaine hydrochloride (HCl) solution, a well -characterized anesthetic/analgesic, with 
more than 35 years of use in the US. 
â€¢ DepoFoam, a liposomal extended- release formulation contained in the marketed product 
DepoCytÂ® (1999). The form of DepoFoam used in EXPAREL has a slightly different mixture of liquid components than that used in DepoCyt. 
7.4. Summary of Human Clinical Experience with EXPAREL  
As of July 2021, the EXPAREL clinical development program consists of 41 premarketing clinical studies: 21 Phase 1 studies, 7 Phase 2 studies, 13 Phase 3 studies; in addition, 21 Phase 4 
(postmarketing) studies have been completed.  Since its approval, EXPAREL has been administered 
to over 9 million subjects in the US ( Investigatorâ€™s Brochure ). 
EXPAREL was well tolerated and had a favorable safety profile when administered as a field block , 
as an interscalene brachial plexus nerve block , and as a combined popliteal and adductor canal 
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  27 of 68 22 OCT 2021  block in varying degrees of vascularity in subjects undergoing various surgical procedures.   The 
frequency and types of events are consistent with the profile of other local anaesthetics.  
At doses up to 665 mg of EXPAREL, no central nervous system (CNS) or cardiovascular system 
AEs observed with high doses of bupivacaine  hydrochloride ( HCl) solution have been observed  
with EXPAREL . Two thorough QTc studies have been conducted; EXPAREL  did not cause 
significant QTc prolongation even at the highest dose evaluated.   
Across all studies, the types and the incidence rates of treatment -emergent AEs (TEAEs)  were 
similar between the EXPAREL  All Doses group (all doses combined) and the bupivacaine HCl 
group.  The  incidence rate for each of the three most common TEAEs (nausea, constipation, and 
vomiting) was lower in the EXPAREL  All Doses group than in the bupivacaine HCl group.   
Study 402-C-333 was conducted to examine the magnitude and duration of the analgesic effect 
achieved with a single dose of EXPAREL  and EXPAREL admixed with bupivacaine HCl  
administered as a combined popliteal and adductor canal block to subjects undergoing lower 
extremity surgeries . EXPAREL (133 mg) was demonstrated to be safe and well tolerated when 
administered as a single dose as a combined popliteal and adductor canal  block . The most frequent 
AEs (ie, nausea, constipation, hypoaesthesia, headache) are consistent wi th those previously seen 
with EXPAREL [ EXPAREL USPI ], suggesting that administration as a combined block doesnâ€™t 
alter the known safety profile of EXPAREL. 
Please see the EXPAREL Full Prescribing Information  for safety information regarding the use of 
EXPAREL  (liposome bupivacaine injectable suspension) for the treatment of postsurgical pain. 
Please refer to the Investigatorâ€™s Brochure  for additional information regarding the completed 
studies.   
7.5. Rationale of the Study  
Pacira is investigating the efficacy, safety, and pharmacokinet ics (PK) of  a single dose of 
EXPAREL administered via adductor canal block in subjects undergoing primary unilateral total 
knee arthroplasty ( TKA ).  
A dose of EXPAREL 10 mL (133 mg) admixed with 10 mL (50 mg) 0.5% bupivacaine HCl is 
expected to provide prolonged pain relief and is safe after TKA compared with 10 mL (50mg) 0.5% 
bupivacaine HCl mixed with 10 mL normal saline when injected in 20 mL volumes as an adductor 
canal block.  The study will also investigate the PK and PD of EXPAREL 133 mg admixed with 50 
mg of 0.5% bupivacaine, and 0.5% bupivacaine 50 mg when administered as an adductor canal block.  
8. OBJECTIVES 
8.1. Primary Objective  
The primary objective is to compare the magnitude of the postsurgical analgesic effect following a 
single dose of EXPAREL  admixed with bupivacaine HCl vs. bupivacaine HCl when administered 
via an adductor canal block in subjects undergoing primary unilateral total knee arthroplasty (TKA) . 
8.2. Secondary Objectives  
The secondary objectives are to :  
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  28 of 68 22 OCT 2021  1. Compare the total postsurgical opioid consumption (in oral morphine equivalents) following a 
single dose of EXPAREL  admixed with bupivacaine HCl vs. bupivacaine HCl . 
2. Compare the time to first opioid consumption  post-surgery, following a single dose of 
EXPAREL  admixed with bupivacaine HCl vs. bupivacaine HCl . 
3. Characterize and compare the magnitude of the duration of sensory and motor block following 
a single dose of EXPAREL admixed with bupivacaine HCl and bupivacaine HCl.  
4. Assess the safety, and pharmacokinetic (PK) profile of EXPAREL admixed with bupivacaine 
HCl and bupivacaine HCl. 
9. OVERALL STUDY DESIGN AND PLAN  
9.1. Study Design  
This is a Phase 3, multicenter, randomized, double -blind, active -controlled, study in approximately 
160 subjects undergoing primary unilateral TKA under spinal anesthesia. The study will have 2 
cohorts. Both cohorts will enroll in parallel.  
 
Cohort 1 ( PK, PD, Efficacy, and S afety ): 
Cohort 1 will enroll a pproximately 40 subjects (20 subject s per treatment arm) undergoing primary 
unilateral TKA under spinal anesthesia to obtain information on PK profile , PD, efficacy,  and 
safety. Subjects in this cohort will be randomized (1:1) to receive an adductor canal block with a 
single dose of  either  EXPAREL 10 mL (133 mg) admixed with 10 mL 0.5% bupivacaine HCl (50 
mg) or 10 mL 0.5% bupivacaine HCl (50 mg)  mixed with 10 mL normal saline. The total dose 
volume will be consistent (20 mL) for all subjects.  
 
Cohort 2 (E fficacy and Safety):  
Cohort 2 will enroll approximately 120 subjects (60 subjects per treatment arm) undergoing primary 
unilateral TKA under spinal anesthesia to obtain information on efficacy and safety . Subjects in 
this cohort will be randomized  (1:1) to receive an adductor canal block with a single dose of either 
EXPAREL 10 mL (133 mg) admixed with 10 mL 0.5% bupivacaine HCl (50 mg) or 10 mL 0.5% 
bupivacaine HCl (50 mg)  mixed with 10 mL normal saline . The total dose volume will be consistent 
(20 mL) for all subjects.   An adaptive study design will be used in this study. An interim analysis to evaluate the sample size 
assumptions and evaluate futility  will occur when a total of approximately 80 subjects  (40 subjects 
in each arm)  combined from either Cohort 1 or Cohort 2 have enrolled and provided complete 
assessment data for the primary efficacy outcome.  
  
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  29 of 68 22 OCT 2021  Figure 1: Study Schema  
 
9.2. Duration of the Study and Subject Participation  
Participation will begin upon signing of the ICF. No more than 45 days should pass between the 
time consent is obtained  and the administration of study drug. Study drug administration will be on 
the same day of surgery. A final follow-up phone call will occur on Post- operative Day ( POD) 1 4 
(Â±3 days). 
The time from study drug administration until the end of participation is  POD 14 (Â±3 days) .  
Therefore, subjects may participate in the study for up to 62 days. 
9.2.1 Study Stopping Rules  
If Pacira, the Investigator, or officials from regulatory authorities discover conditions during the 
study that indicate that  the study or study site should be terminated, this action may be taken after 
Pacira has consulted with appropriate regulatory authorities and notified the Investigator(s). 
The Pacira Medical Monitor and Pharmacovigilance team will review all serious adverse events 
(SAEs) reported from Pacira clinical studies on an ongoing basis and in real time (i.e., as the events 
are reported). The Medical Monitor is responsible for temporarily pausing the study if the type, frequency, or seriousness/severity of such events suggests a potential threat to the safety of the study subjects. If such action is taken, a thorough review of all available data will be performed. Based on the results of this review and discussions with Investigators and/or regulatory authorities, 
the study may be restarted or permanently terminated as warranted. 
In addition, any death will be thoroughly reviewed, and appropriate action taken. The following adverse event study stopping rules will be applied: 
â€¢ The study will be stopped after 1 death where a clear alternate cause is not readily apparent.  

Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  30 of 68 22 OCT 2021  â€¢ The study will be stopped after 2 non -fatal serious adverse events where a clear alternate 
cause is not readily apparent.  
â€¢ The study will be stopped after 2 moderate to severe symptoms deemed definitely r elated 
to local anesthetic systemic toxicity . 
9.3. Discussion of Study Design  
This Phase 3, multicenter, randomized, double -blind, active -controlled study will enroll 
approximately 160 subjects to evaluate the efficacy  and safety of EXPAREL  133 mg admixed with 
0.5% bupivacaine HCl  and 0.5% bupivacaine HCl when administered as an adductor canal block, 
in subjects undergoing primary unilateral TKA. 
Only Cohort 1 subjects ( 40 subjects) will provide blood samples for PK assessments and will be 
assessed for PD. Subjects in Cohort 1 will also provide information on efficacy and safety of  
EXPAREL 133 mg admixed with 0.5% bupivacaine HCl (50 mg) and 0.5% bupivacaine HCl (50 
mg). 
Cohort 2 subjects ( 120 subjects) will provide information on efficacy and safety of EXPAREL  133 
mg admixed with 0.5% bupivacaine HCl (50 mg) and 0.5% bupivacaine HCl (50 mg). 
The two treatment arms of the study for Cohort 1 and Cohort 2 are as follows:  
1. EXPAREL admix arm: subjects  randomized to this treatment arm will receive 10 mL (133 
mg) EXPAREL admixed with 10 mL (50 mg) 0.5% bupivacaine HCl. 
2. Bupivacaine HCl arm:   subjects randomized to this treatment arm will receive 10 mL (50 
mg) 0.5% bupivacaine HCl mixed with 10 mL normal saline. 
10. STUDY POPULATION  
Approximately 160 adult subjects undergoing primary unilateral TKA under spinal anesthesia will 
be enrolled in the study.  
10.1. Inclusion Criteria  
Subjects eligible for study entry must meet all of the following criteria:  
1. Male or female, ages 18 or older at screening. 
2. Indicated to undergo primary unilateral total knee arthroplasty under spinal anesthesia.  
3. Primary indication for TKA is degenerative osteoarthritis of the knee. 
4. American Society of Anesthes iologists (ASA) physical status 1, 2, or 3 (see Appendix 5, 
Section  18.5).  
5. Able to provide informed consent, adhere to the study schedule, and complete all study 
assessments.  
6. Body Mass Index (BMI) â‰¥18 and <40 kg/m2. 
10.2. Exclusion Criteria  
A subject will not be eligible for the study if any of the following criteria are met:  
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  31 of 68 22 OCT 2021  1. Allergy, hypersensitivity, intolerance, or contraindication to any of the study medications 
for which an alternative is not named in the protocol (e.g., amide -type local anesthetics, 
opioids, bupivacaine HCl, NSAIDs). 
2. Planned concurrent surgical procedure (e.g., bilateral TKA). 
3. Undergoing unicompartmental TKA or revision TKA. 
4. Concurrent painful physical condition ( e.g., arthritis, fibromyalgia, cancer) that may require 
analgesic treatment with NSAIDs or opioid s in the post dosing period for pain that is not 
strictly related to the knee surgery and which, in the Investigatorâ€™s opinion, may confound 
the post dosing assessments. 
5. Inadequate sensory function below the knee as assessed by the Investigator. 
6. History of contralateral TKA within 1 year. 
7. Previous open knee surgery on the knee being considered for TKA. Prior arthroscopy is permitted.  
8. History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years. 
9. Administration of an investigational drug within 30 days or 5 elimination half -lives of such 
investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subjectâ€™s participation in this study.  
10. Previous participation in an EXPAREL study. 
11. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the Investigator, could interfere with study assessments or compliance. 
12. Currently pregnant, nursing, or planning to become pregnant during the study.  
13. Clinically significant medical disease th at, in the opinion of the Investigator, would make 
participation in a clinical study inappropriate. This includes diabetic neuropathy, coagulation or bleeding disorders, severe peripheral vascular disease, renal insufficiency, hepatic dysfunction or other conditions that would constitute a contraindication to participation in the study. 
14. Currently on a neuromodulating agent (e.g., gabapentin, pregabalin [Lyrica], duloxetine [Cymbalta], etc.)].  
15. Current use of systemic glucocorticoids within 30 days of randomi zation  in this study. 
16. Use of dexmedetomidine HCl (PrecedexÂ®)  or clonidine  within 3 days of study drug 
administration.  
17. Any use of marijuana [including Tetrahydrocannabinol (THC) and Cannabidiol (CBD)] within 30 days prior to randomization, or planned use during the course of the study. 
18. Chronic opioid use  (average â‰¥30 oral morphine equivalents/day) within 30 days prior to 
randomization.  
Given the COVID-19 pandemic, if there is a concern about a subject's recent or potential exposure to COVID- 19, or if the subject is not medically fit/cleared for surgery due to suspected COVID -19 
illness/symptoms, the subject must be excluded per Exclusion criterion #13. 
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  32 of 68 22 OCT 2021  10.3. Removal of Subjects from Therapy or Assessment  
Every reasonable effort should be made to maintain subject compliance and participation in the 
study. Reasons for discontinuation of any subject from the study will be recorded. 
If any clinically significant event or condition is uncovered during the study period (e.g., excessive 
bleeding, acute sepsis) th at might render the subject medically unstable or compromise the subjectâ€™s 
postsurgical course, the subject should be withdrawn from the study and the event or condition should be reported as an AE or SAE. 
If a subject who withdraws from the study has an ongoing AE, every effort must be made to follow 
such events until satisfactory resolution is obtained, or further follow -up is otherwise no longer 
warranted.  
10.3.1. Withdrawal Secondary to Adverse Events 
If a subj ect experiences an AE that renders the subject incapable of continuing with the remaining 
assessments, the subject will be discontinued from further participation in the study. A final 
evaluation, including the End of Study assessments (see Section 10.3.3), should be performed so 
that the subjectâ€™s study participation can be terminated in a safe and orderly manner.  
Any subject who discontinues because of an AE should be instructed to notify the study personnel 
of any abnormal symptoms and to come to the study site if medical evaluation is needed and the urgency of the situation permits. Any subject exhibiting AEs will receive appropriate treatment at the discretion of the Investigator until resolution of the AE.  
This study involves a single administration of the study drug; therefore, subjects should not be terminated from the ongoing study assessments as long as they are willing and able to continue with 
the follow -up schedule according to the protocol. For emergencies and other unscheduled visits to 
a medical facility other than the study site, medical records must be obtained by the Investigator 
and appropriate information captured in the subjectâ€™s case report form ( CRF).  
In addition, the subject may be withdrawn from the study if the subject meets the following criterion 
during or after the surgery:  
Any clinically significant event or condition uncovered during the surgery (e.g., excessive bleeding, 
acute sepsis) th at, in the opinion of the Investigator, renders the subject medically unstable or 
complicates the subjectâ€™s postsurgical course.  
10.3.2. Voluntary or Study Investigator Withdrawal 
Subjects are free to discontinue from the study at any time, without prejudice to future treatment. 
A subject may be discontinued from the study if the subject refuses study treatment (i.e., the adductor canal block) or refuses to comply with study procedures. Subjects should be encouraged to complete the study safety assessments. Reasons  for discontinuation from the study will be 
recorded.  
If a subject is discontinued by the Investigator or voluntarily withdraws from the study after 
receiving the study drug, the subject will be asked to complete a final evaluation, including the early termination assessments (see Section 10.3.3), so that the subject can be withdrawn in a safe and 
orderly manner. 
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  33 of 68 22 OCT 2021  After termination from the study, the subject may be followed for safety including monitoring of 
AEs/SAEs  through POD 14. 
10.3.3. Early Termination Assessments  
In case of early termination, the following assessments shall be performed:  
â€¢ Record date and time of withdrawal  
â€¢ Record reason for withdrawal 
â€¢ Review adverse events; any ongoing AEs/SAEs will need to be followed to resolution 
â€¢ Record responses to pain assessment:  
o Pain intensity scores (using the NRS) measured as â€œOn a scale from 0 to 10, where 
0 equals no pain and 10 equals the worst possible pain, how much pain are you experiencing in your operative knee right now ?â€ 
o Pain intensity scores (using the NRS) measured as â€œOn a scale from 0 to 10, where 
0 equals no pain and 10 equals the worst possible pain, what was the worst  pain in 
your operative knee in the last 24 hours?â€ 
o Pain intensity scores (using the NRS) measured as â€œOn a scale from 0 to 10, where 
0 equals no pain and 10 equals the worst possible pain, what was the average  pain 
in your operative knee in the last 24 hours?â€ 
 
11. TREATMENTS 
11.1. Treatments to be Administered  
Treatments for Cohort 1 and Cohort 2:  
 On the day of surgery, subjects will receive an ultrasound- guided adductor canal block with one of 
the following treatments  (study drug): 
1. EXPAREL admix arm:  subjects randomized to this tr eatment arm will receive 10 mL 
(133 mg) EXPAREL admixed with 10 mL (50 mg) 0.5% bupivacaine HCl 
2. Bupivacaine HCl arm : subjects randomized to this treatment arm will receive 10 mL 
(50 mg) 0.5% bupivacaine HCl mixed with 10 mL normal saline.   
 Block Procedure:  
Subjects may be lightly sedated with 1 to 2 mg of midazolam intravenously (IV) before the nerve block procedure. The study drug (EXPAREL admixed with bupivacaine HCl or bupivacaine HCl) will be administered under ultrasound guidance 90 min (Â±30 min) prior to surgery. A peripheral 
nerve stimulator will be used to confirm nerves in the adductor canal before study drug administration (see Section 13.3). A confirmatory ultrasound video will be captured during the 
nerve block procedure  (during hydrodissection by saline injection and study drug administration) , 
with needle in place to ensure accurate block placement. The Investigator will provide the video to the sponsor within 24 hours from the end of block procedure that will be reviewed by an 
independent ultrasound adjudication committee to ensure accuracy of study drug administration. Only two unblinded study drug administrators (anesthesiologis t) will be assigned per site to perform 
the block procedures  unless approved in advance in writing by the Sponsor on a case -by-case basis.  
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  34 of 68 22 OCT 2021  The designated study drug administrators (anesthesiologist) will not participate in any other study 
related assessments after randomization. 
For all study arms, the total volume of 20 mL will be administered as the adductor canal block.    11.1.1. Study Drug Administration Considerations  
As there is a potential risk of severe AEs associated with the administration of local anesthetics, the 
study site must be equipped to treat subjects with evidence of cardiac toxicity.   
EXPAREL may not be administered to a subject if the vial has been open for more than 4 hours.  
In order to prevent EXPAREL from settling, gently invert and re invert the vials of EXPAREL 
multiple times to re -suspend the particles immediately prior to withdrawal from the vial. Similarly,  
inverting and re- inverting the syringe prior to administration is required .   
As recommended  in the EXPAREL Full Prescribing Information, no other drugs  (e.g., epinephrine, 
dexamethasone, clonidine) are to be admixed with EXPAREL other than bupivacaine HCl. 
Lidocaine and other local anesthetics  are not permitted to be locally administered during the surgery 
because they are known to interact with EXPAREL, resulting in the displacement of bupivacaine and elevated plasma levels. When a topical antiseptic is applied to the surgical site, the solutions should not be allowed to come in contact with each other (e.g., the area must be dry before EXPAREL is administered). Upon discovering use of any prohibited therapy and/or medication during or after surgery, the Investigator should document all events that led to the deviation, write 
a note to file, and notify the Pacira Medical Monitor accordingly 
11.1.2. Bupivacaine HCl Administration Considerations 
Given the potential risk of severe adverse effects associated with bupivacaine HCl, the study sites 
must be equipped to manage subjects with any evidence of cardiac, neurological, or respiratory toxicity.   
Bupivacaine HCl is contraindicated in subjects wi th known hypersensitivity to amide -like local 
anesthetics. Caution must be exercised to prevent incidental intravenous administration of 
bupivacaine during block placement. 
11.2. Iden tity of Investigational Product s 
11.2.1. Description of EXPAREL  
EXPAREL (bupivacaine li posome injectable suspension) is formulated as a sterile, non-pyrogenic, 
white to off -white, preservative -free homogenous suspension of bupivacaine encapsulated into 
multivesicular liposomes (DepoFoam drug delivery system). Bupivacaine is present at a nomi nal 
concentration of 13.3 mg/mL. For this study, EXPAREL will be provided in 20 mL , 1.3% (13.3 
mg/mL) single -use, clear glass vials. EXPAREL vials should be stored refrigerated at 2Â°C to 8Â°C 
(36Â°F to 46Â°F ). 
11.2.2. Description of Reference Product  
The reference pr oduct will be 0.5% bupivacaine HCl  to be administered via adductor canal block. 
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  35 of 68 22 OCT 2021  11.2.3. Description of Volume Expansion Agent  
Normal saline (0.9% sodium chloride solution) for injection will be used for the expansion of study 
drug volume for the 0.5% bupivacaine HCl arm .    
11.3. Method of Assigning Subjects to Treatment  
11.3.1. Randomization Scheme  
This is a randomized study. Cohort 1 will enroll approximately 40 total subjects undergoing primary 
unilateral TKA randomized 1:1 in the EXPAREL admix arm and bupivacaine HCl arm.   
Cohort 2 will enroll approximately 120 total subjects undergoing primary unilateral TKA, 60 
subjects in each treatment arm; EXPAREL admix arm and bupivacaine HCl arm. Subjects will be 
randomized 1:1 to treatment arm s.  
The randomization code will be generated by a centralized randomization system, which will also 
be used to communicate subject randomizations to study sites. All randomized subjects will have 
both a unique subject identifier and a unique randomization code. No subject or randomization code identifiers will be reused once assigned . 
11.3.2. Randomization Procedures  for Treatment Assignment  
Once a subject is identified as being qualified to participate in the study (see Section  10), and is at 
the study site for surgery, the Investigator or designee will obtain a randomization assignment.  The 
subject will be considered randomized into the study once the study treatment is assigned . 
11.3.3. Replacement of Subjects  
Subjects who are withdrawn from the study before receiving study drug may be replaced.  Once assigned, subject numbers will not be reused; subjects enrolled to replace those who withdraw 
will be assigned a unique subject number  and randomized to treatment according to the procedures 
outlined above. Subjects who are randomized but are withdrawn from the study before receiving 
study drug or do not undergo the surgical procedure may be replaced. Additionally, subjects may be replaced if insufficient and/or incomplete data are noted on PK profiles or efficacy endpoints. 
11.4. Selection of Doses in the Study  
During the clinical development of EXPAREL, single doses ranging from 2 mg to 665 mg have been safely administered via various routes.  Pharmacokinetic studies have shown that because 
EXPAREL releases bupivacaine gradually as the lipid structure breaks down, administration of 
EXPAREL 266 mg results in a maximum plasma concentration equivalent to that seen with 
standard bupivacaine HCl 100 mg. Clinical studies have shown that, for wound infiltration, a total 
dose of 266 mg (20 mL) of EXPAREL is safe and efficacious. Based on this experience, the FDA -
approved marketed dose of 266 mg was deemed appropriate for this study. 
As a part of the cli nical development program, a Phase 3 study (402-C- 333) evaluating the PK, PD, 
efficacy, and safety of EXPAREL as a combined sciatic nerve (in popliteal fossa) and saphenous 
nerve (in adductor canal) block in subjects undergoing lower extremity surgeries was conducted. 
Both EXPAREL (266 mg) and EXPAREL admix arms were safe, compared to bupivacaine HCl arm. Pacira would like to evaluate and compare efficacy and safety along with PK concentrations 
of EXPAREL 133 mg admixed with bupivacaine HCl 50 mg vs. bupiva caine HCl 50 mg  for the 
adductor canal block when used  for the more painful procedures like TKA. 
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  36 of 68 22 OCT 2021  11.5. Blinding  
11.5.1. Blinding Procedures  
EXPAREL admixed with 0.5% bupivacaine HCl, and 0.5% bupivacaine HCl are visually 
distinguishable; therefore, to maintain the doubl e-blind study design, the individuals preparing and 
administering study drug, or transporting unblinded drug will not be allowed to perform any of the 
study assessments after randomization (with the possible logistical exception of drawing blood in the operating room (OR) to be processed by blinded staff for the PK assessments) or reveal the assigned study treatment to any other members of the study team at any time. Additionally, efforts will be made to prevent the subject from observing the study drug syringe. Syringes containing study drug will need to be gently inverted several times to re -suspend any settling of the study drug 
that may have occurred prior to administration. The administration of study drug will be recorded using the minimal amount of in formation necessary to avoid unblinding staff who will be 
participating in blinded procedures. 
Staff members conducting study- specific, postsurgical assessments and the subjects will remain 
blinded to the assigned treatment throughout the study in part by not being present during the 
administration of the nerve blocks. The site PI must be blinded to the study drug and will not be 
involved in and/or present during study drug administration procedure. 
If a subject experiences an SAE, Pacira will not automatically unblind the subjectâ€™s treatment, 
unless it is necessary to manage treatment of the SAE. Ex pedited SAEs will be unblinded by Pacira 
for regulatory reporting purposes. 
At each site, only the designated unblinded study staff  will receive unblinded randomization 
assignments; the designated unblinded pharmacist or administrator will be responsible f or preparing 
the study drug.  Only t he two designated unblinded study drug administrators (anesthesiologist) at 
each site will be permitted to administer study drug. 
No crossover will be permitted between the blinded and unblinded study site personnel throughout 
the study. The assignment of site monitors will also be segregated. Blinded monitors will review CRFs, clinic charts, and all other study- related documents that do not disclose the allocation of 
study treatment. Care should be taken in recording and review of operating room (OR) records to 
not record information in an unblinded fashion. Pharmacy or any other clinic records providing unblinded information (e.g., randomization, study drug preparation, study drug accountability, study drug administration) will be reviewed by specialized unblinded monitors who will notify Pacira of treatment noncompliance.  
The independent review committee conducting the interim analyses will not be blinded to the study drug. 
Additional details are outlined in the study- specific Blinding Plan. 
11.5.2. Unblinding Procedure 
Blinded study personnel should not be unblinded to the subject treatment assignments during the 
study. The I nvestigator will have the ability to unblind a subject through the randomization system 
if it is felt that subject safety warrants such unblinding. However, if possible, the Investigator should 
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  37 of 68 22 OCT 2021  discuss the safety issues with the Pacira Medical Monitor befo re attempting such unblinding. Any 
unblinding will be documented through immediate notification of the Pacira study team and the 
Investigator within the interactive response technology system used for randomization. The reason 
for unblinding will be documented. Any accidental unblinding events (i .e., through mishaps in the 
operating room or miscommunication among study staff) must be reported to Pacira immediately.  
Any unblinding performed through the randomization system will be recorded as a transaction, and 
the appropriate study personnel will be notified that such a transaction occurred. Any incidence(s) 
of unblinding will be noted in the clinical study report with a full discussion of the events leading to the decision to unblind.  
11.6. Prior and Concomitan t Therapy and Medications  
Concomitant medications will be coded using the World Health Organization Drug Dictionary. The number and percent of subjects taking concomitant medications will be tabulated for each treatment group by Anatomic Therapeutic Chemic al class and preferred terms.  
11.6.1. Before Study Drug Administration  
All subjects must receive the following medication within 4 hours prior to surgery: 
â€¢ Celecoxib 200 mg, orally (PO) 
Other P ermitted Prior Medications and Therapy: 
â€¢ 1-2 mg of midazolam (Versed) 
â€¢ Ondansetron  
Restricted Prior Medications and Therapy: 
â€¢ Systemic glucocorticosteroids and neuromodulating agents (e.g., gabapentin, pregabalin 
[Lyrica], duloxetine [Cymbalta], etc.). 
â€¢ Long- acting or sustained release opioid medications and NSAIDs (except for low -dose aspirin 
used for cardio protection) are not permitted within 3 days of study drug administration. 
â€¢ Dexmedetomidine HCl (Precedex)  and clonidine  use is not permitted within 3 days of study 
drug administration. 
â€¢ Scopolamine Patch  is not pe rmitted.  
â€¢ No opioid medications are permitted within 24 hours of study drug administration. 
â€¢ Use of an investigational drug within 30 days or 5 elimination half -lives of such investigational 
drug, whichever is longer, prior to study drug administration, or planned administration of 
another investigational product or procedure during the subjectâ€™s participation in this study is not permitted.  
â€¢ No drugs (other than the described bupivacaine HCl admixture) are to be admixed with study 
drug (e.g., epinephrine, dexamethasone, clonidine).  
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  38 of 68 22 OCT 2021  â€¢ Lidocaine (except, if used as a local anesthetic at the site of IV placement)  and other local 
anesthetics will not be permitted to be locally administered in the area of the nerve block 
administration other than use in a superficial cutaneous wheal for needle insertion. 
11.6.2. Perioperative  
â€¢ All subjects will receive an infiltration between the popliteal artery and capsule of the knee 
(IPACK) under ultrasound guidance with 15 mL of 0.25% bupivacaine HCl  (37.5 mg)  
immediately follo wing  study drug administration (should be done with the same set -up for the 
nerve block). 
â€¢ All subjects will receive spinal anesthesia  immediately prior to surgery  with 0.5% bupivacaine 
HCl ( up to 15 mg). If the spinal  fails or cannot be completed, the subject may receive total 
intravenous anesthesia (TIVA).  
â€¢ All subjects will receive a dose of 1000 mg of intravenous (IV) acetaminophen at the time of 
surgical incision  
â€¢ Propofol is permitted for induction and intra-operative sedation . 
Other Permitted medications: 
â€¢ Tranexamic acid (TXA) is permitted . 
Restricted  Medications:  
â€¢ No other medication (including opioids) should be mixed with the bupivacaine for spinal anesthesia  
â€¢ The use of dexamethasone, acetaminophen/paracetamol, ketorolac, or other NSAIDs will not 
be permitted preemptively or intraoperatively except for emergency use to treat an AE.  
â€¢ Intraoperative use of opioids (except IV fentanyl, not to exceed 1 ug/kg unless deemed 
medically necessary) and ketamine will not be permitted.  
11.6.3. Post-Surgery  
â€¢ All subjects will receive one post -operative dose of 1000 mg of IV acetaminophen, administered 
approximately 8 hours after the first dose ( approximately 8 hours after incision).  The maximum 
total dose will not exceed 2000 mg.  No additional acetaminophen is permitted after the second 
IV acetaminophen dose.  
Other Permitted  Medicati ons: 
â€¢ Ondansetron or metoclopramide may be used for postoperative nausea and vomiting.  
â€¢ Postsurgical pain medications for breakthrough pain as outlined in Section 11.7.  
Restricted  Medications:  
â€¢ No other analgesics, including fentanyl, are permitted within 96 hours after surgery.  
â€¢ Scopolamine patch  is not permitted.  
â€¢ Dexmedetomidine HCl (Precedex) use is not permitted .  
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  39 of 68 22 OCT 2021  â€¢ Lidocaine (except, if used as a local anesthetic at the site of IV placement)  and other local  
anesthetics will not be permitted to be locally administered in the area of the nerve block 
administration through POD 7. 
â€¢ Patient control analgesia ( PCA ) is not permitted . 
â€¢ Systemic glucocorticosteroids and neuromodulating agents (e.g., gabapentin, pregabalin [Lyrica], duloxetine [Cymbalta], etc.). 
11.7. Postsurgical Pain Medication for Breakthrough Pain  
An unscheduled pain intensity assessment using the NRS (measured as â€œOn a scale from 0 to 10, 
where 0 equals no pain and 10 equals the worst possible pain, how much pain are you experiencing in your operative knee right now ?â€) must be completed immediately prior to administration of any 
breakthrough pain medication up to 96 hours post-surgery.  
Oxycodone will be administered  on an as needed (PRN) basis for breakthrough pain through 96 
hours post -surgery ; opioids should not be given on a pre -determined schedule. Immediate release 
oral (PO) oxycodone will be administered in a stepwise approach: 
â€¢ Initial dose of 5 mg oxycodone may be offered. 
â€¢ If the initial opioid dose is insufficient for pain relief, an additional 5 mg oxycodone ma y be 
offered up to a maximum of 10 mg (total dose) 
â€¢ If a subject is unable to tolerate PO medication (or the PO oxycodone pain relief is insufficient), 
IV morphine (initiated at 2 mg) or hydromorphone (initiated at 0.2 mg) may be administered. 
No NSAIDs or other opioids including Tramadol are allowed for the breakthrough pain 
management per protocol. No Acetaminophen (other than the scheduled IV acetaminophen) should 
be used for breakthrough pain. 
For study purposes, it is important to standardize pain management modalities during the first 96 
hours post- surgery . Therefore, the s tudy staff must adhere closely to the treatment options and 
requirements noted in the protocol. After 96 hours, the analgesic regimen may be adjusted for each subject individually as deemed appropriate by the physician responsible for the postsurgical care. 
All postsurgical analgesics administered  (opioids and other analgesics), must be recorded through 
hospital discharge. 
11.8. Treatment Compliance  
Study drug (EXPAREL admix, or bupivacaine HCl)  administration will be performed by an 
unblinded study Investigator (anesthesiologist) qualified by experience and training. All details of study drug administration , including dose volume and start and stop time, will be  
recorded in a bli nded fashion in the source and e CRF.  
11.9. Accountability of Study Drug  
The Investigator or designee ( e.g., pharmacist) is responsible for maintaining current and accurate 
inventory records.  At a minimum, the Investigator or designee will maintain accurate reco rds 
demonstrating dates and units of drug received, lot numbers, subjects to whom drug was 
administered, and accounts of any drug destroyed accidentally or deliberately.  The Investigator 
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  40 of 68 22 OCT 2021  must retain vials containing used, unused, or expired EXPAREL for return or destruction, as 
instructed by Pacira, following confirmation of drug accountability data by an unblinded study 
monitor.  A  record of drug return or destruction will be maintained and provided to Pacira.  
Inventory records must be readily available for inspection by the unblinded study monitor and 
appropriate regulatory authorities at any time.  A copy of the inventory records, drug accountability information, and notice of return or destruction will be returned to Pacira at the end of the study.  Only authorized personnel identified by the Investigator will have the ability to access and 
administer the drug. 
12. STU DY ENDPOINTS AND MEASUREMENTS  
12.1. Efficacy A ssessments 
â€¢ Pain intensity measured using the NRS as â€œOn a scale from 0 to 10, where 0 equals no pain and 
10 equals the worst possible pain, how much pain are you experiencing in your operative knee right now ?â€  will be assessed:  
o Upon arrival in the Post- anesthesia Care Unit (PACU) (Â±5 min)  
o Every 15 minutes in the PACU (Â±5 min) 
o At PACU discharge (Â±5 min)  
o Every 6 hours from the end of surgery until 96 hours post -surgery: 6 h (Â±2 h), 12 h (Â±2 
h), 18 h (Â±2 h), 24 h (Â±2 h), 30 h (Â±2 h), 36 h (Â±2 h), 42 h (Â±2 h), 48 h (Â±2 h), 54 h (Â±2 h), 60 h (Â±2 h), 66 h (Â±2 h), 72 h (Â±2 h), 78 h (Â±3 h), 84 h (Â±3 h), 90 h (Â±3 h), and 96 h (Â±3 h) 
â€¢ An unscheduled pain intensity assessment using NRS as â€œOn a scale from 0 to 10, where 0 equals no pain and 10 equals the worst possible pain, how much pain are you experiencing in 
your operative knee right now ?â€ will be obtained immediately prior to administration of any 
breakthrough pain medication until 96 hours post- surgery . 
â€¢ Pain intensity using the NRS at 24 (Â±2 h), 48 (Â±2 h), 72 (Â±2 h), and 96 (Â±3 h) post -surgery,  
measured as â€œOn a scale from 0 to 10, where 0 equals no pain and 10 equals the worst possible 
pain, what was the worst pain in your operative knee in the last 24 hours?â€ 
â€¢ Pain intensity using the NRS at 24 (Â±2 h), 48 (Â±2 h), 72 (Â±2 h), and 96 (Â±3 h) post -surgery,  
measured as â€œOn a scale from 0 to 10, where 0 equals n o pain and 10 equals the worst possible 
pain, what was the average pain in your operative knee in the last 24 hours?â€ 
Subjects will be instructed to focus all NRS pain intensity ratings on the operative knee, and no other locations where they may be experiencing pain. 
In addition, subjectâ€™s satisfaction with pain management using 1 question from the International 
Pain Outcome (IPO) questionnaire will be recorded at 96 hours (Â±3 h) post-surgery. 
12.2. Efficacy Endpoints  
Primary Efficacy Endpoint: 
â€¢ The area under the curve (AUC) of NRS pain intensity scores from 0-96 hours post-surgery. 
Secondary Efficacy Endpoints:  
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  41 of 68 22 OCT 2021  â€¢ Total postsurgical opioid consumption in oral morphine equivalents (OMED) from 0 to 
96 hours post-surgery. 
â€¢ Time to first opioid consumption post- surgery . 
â€¢ Worst and average NRS pain intensity scores through 24h, 48h, 72h, and 96h from the end of surgery. 
12.3. Safety Assessments  
The following safety assessments will be conducted by blinded study staff at the time points 
specified:  
â€¢ SAEs will be recorded fr om the time of informed consent and AEs will be recorded from the 
time of randomization through POD 14. 
12.4. Safety Endpoints  
â€¢ Incidence of  treatment- emergent AEs ( TEAEs ) and SAEs from start of the nerve  block 
procedure through POD 14. 
12.5. Pharmacokinetic  Assessments ( Cohort 1  only)  
The blood samples for PK assessment will be obtained from the Cohort 1 subjects. A total of 17 
PK samples will be collected for each subject  in Cohort 1. These samples will be obtained at Predose 
(up to 15 min before block), 30 min (Â±5 min), 45 min (Â±5 min), and 1 h (Â±15 min), 2 h (Â±30 min), 
8 h (Â±30 min), 12 h (Â±30 min), 24 h (Â±1 h), 30 h (Â±1 h), 48 h (Â±1 h), 60 h (Â±2 h), 72 h (Â±2 h), 84 h 
(Â±2 h), 96 h (Â±3 h), 120 h (Â±3 h), 144 h (Â±3 h), and 168 h (Â±3 h) hours from end of block procedur e 
(See Table 2 ). 
12.6. Pharmacokinetic Endpoints ( Cohort 1  only)  
The following PK endpoints will be determined:  
â€¢ Area under the plasma concentration -versus -time curve (AUC)  
â€¢ Maximum plasma concentration (C max) and time of C max (Tmax) 
â€¢ The apparent terminal elimination half- life (t 1/2el) 
â€¢ Apparent clearance (CL/F)  
â€¢ Apparent volume of distribution (Vd) 
12.7. Pharmacodynamic Assessments ( Cohort 1  only)  
Pharmacodynamic assessments must be performed by blinded, trained , licensed medical staff (e.g., 
Physician, Registered Nurse, Physician Assistant) and documented on the Investigatorâ€™s study 
Delegation Log. A limited number of study staff  (blinded to the study drug assignment)  should 
perform the sensory/motor assessments. 
Assessment of sensory functions (Light Touch Assessment): 
â€¢ Sensory assessment for light touch will be performed at pre -dose (up to 15 min before block), 
15 min (Â±5 min), 30 min (Â±5 min), 45 min (Â±5 min), 1 h (Â±15 min), 2 h (Â±30 min), 8 h (Â±30 
min), 12 h (Â±30 min), 24 h (Â±1 h), 30 h (Â±1 h), 48 h (Â±1 h), 60 h (Â±2 h), 72 h (Â±2 h), 84 h (Â±2 h), 96 h (Â±3 h), 120 h (Â±3 h), 144 h (Â±3 h), and 168 h (Â±3 h) from the end of the nerve block 
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  42 of 68 22 OCT 2021  procedures, or until full sensory function has returned to baseline (pre -dose ) levels  (see 
Appendix 3, Section 18.3) . Each light touch area of assessment will be rated independently. 
Additional unscheduled assessments may be performed, particularly around the surgery, if no 
onset of block is noted on the last scheduled assessment prior to surgery.   For each sensory assessment performed, both locations mentioned below will be assessed for 
light touch. If at the  168-h assessment there is a sensory deficit, the incident will be recorded as 
an AE. The physician will assess the subject for other etiologies that may explain the persistent 
sensory deficit. If the sensory deficit persists at the  168-h assessment , the subject is to return 
for unscheduled visit(s) at the Investigator's discretion until the sensory function has returned.   Sensory function assessment will include the following two locations:   1. Proximal - Medial aspect of the lower leg (3 -4 cm bel ow the knee)   
2. Distal - Medial aspect of the lower leg (3 -4 cm above ankle)  
 
Onset of sensory block  will be defined as the earliest timepoint with loss of light touch sensation 
along the distribution of the target nerve distal to the site of the block. 
Offset of sensory block  will be defined as the first timepoint of return  of light touch sensation 
along the distribution of the target nerve distal to the site of the bloc k. After offset of sensory 
assessments are noted ( light touch sensation in both test areas  in a single  assessment ), no subsequent 
assessments will be required.  
Duration of sensory block will be defined as the time between onset and offset of light touch sensation . 
Assessment of motor function: 
Motor function (onset and offset of motor block) will be assessed by active movement of the knee  
(knee extension). This will be used to determine the duration of the motor blockade. 
â€¢ The motor function test will be performed at pre -dose (up to 15 min before block), 15 min (Â±5 
min), 30 min (Â±5 min), 45 min (Â±5 min), 1 h (Â±15 min), 2 h (Â±30 min), 8 h (Â±30 min), 12 h (Â±30 
min), 24 h (Â±1 h), 30 h (Â±1 h), 48 h (Â±1 h), 60 h (Â±2 h), 72 h (Â±2 h), 84 h (Â±2 h), 96 h (Â±3 h), 120 h (Â±3 h), 144 h (Â±3 h), and 168 h (Â±3 h) from the end of the block procedures, or until motor function has returned to baseline (pre -dose) level  (see Appendix 4, Section 18.4) . Once the 
offset  of motor block is recorded and documented, no further scheduled motor assessments are 
required. Additional unscheduled assessments may be performed, particularly around the surgery, if no onset of block is noted on the last scheduled assessment prior to surgery.   If at the  168-h assessment there is a motor function deficit, the incident will be recorded as an 
AE. The physician will assess the subject for other etiologies that may explain the persistent motor deficit. If the motor deficit persists at 168 h, the subject is to return for unscheduled 
visit(s) at the Investigator's discretion until the motor function has returned . 
Onset of motor block  will be defined as the earliest timepoint with no knee extension. 
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  43 of 68 22 OCT 2021  Offset of motor block  will be defined as resolution of the motor block with knee extension. After 
offset of motor block is noted, no subsequent assessments will be conducted. 
Duration of motor block  will be defined as time between onset and offset  of motor block. 
12.8. Pharmacodynamic  Endpoints  (Cohort 1 only)  
The following pharmacodynamics endpoints will be determined: 
â€¢ Median time to onset of sensory block and motor block 
â€¢ Median duration of sensory block and motor block 
12.9. Appropriateness of Measures  
The endpoints selected for this study were based on validated methodologies and other well -
established clinical measurements used in the peer reviewed literature. Measurements were further 
refined in this study based on previous nerve block experience with EXPAREL and other Phase 3 or 4 studies. 
13. STU DY PROCEDURES  
A time and  events schedule for all study procedures is provided in Table 1 and Table 2.   
13.1. Instructions for Conducting Procedures and Measures  
All PK, sensory/motor function assessments, and safety assessments conducted after baseline (pre -
dose) will be timed from the end of the block. End of block procedure is defined as the time of 
completion of study drug administration via adductor canal block. 
All NRS scores , vital signs, and EKG  to be collected after surgery will be timed from the end of 
surgery.  
At timepoints when multiple  assessments coincide, assessments will be performed in the following 
sequence:  pain intensity assessment, sensory assessments, motor assessment, blood draw for PK 
assessment , vital signs, 12- lead EKG, as applicable.  
The start of surgery is defined as the time of the first incision. The end of surgery is defined as the time recorded in the surgical record. Postsurgical is defined as after the end of surgery.  
Postsurgical analgesia and collection of study data will take place under the supervision of study 
staff at the site.  
13.1.1. Pain Intensity Assessment  
Pain intensity will be assessed using an 11-point NRS (0-10) as follows: 
â€¢ Pain intensity scores (using the NRS ) measured as â€œOn a scale from 0 to 10, where 0 equals no 
pain and 10 equals the worst possible pain, what was the worst  pain in your operative knee in 
the last 30 days?â€ and â€œOn a scale from 0 to 10, where 0 equals no pain and 10 equals the worst 
possible pain, what was the average  pain in your operative knee in the last 30 days?â€ will be 
assessed on the day of surgery  prior to study drug administration. 
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  44 of 68 22 OCT 2021  â€¢ Pain intensity scores (using the NRS) measured as â€œOn a scale from 0 to 10, where 0 equals no 
pain and 10 equals the worst possible pain, how much pain are you experiencing in your operative knee right now ?â€  will be assessed:  
o Upon arrival in the Post- anesthesia Care Unit (PACU) (Â±5 min)  
o Every 15 minutes in the PACU (Â±5 min) 
o At PACU discharge (Â±5 min) 
o Every 6 hours from the end of surgery until 96 hours post -surgery: 6 h (Â±2 h), 12 h (Â±2 
h), 18 h (Â±2 h), 24 h (Â±2 h), 30 h (Â±2 h), 36 h (Â±2 h), 42 h (Â±2 h), 48 h (Â±2 h), 54 h (Â±2 h), 60 h (Â±2 h), 66 h (Â±2 h), 72 h (Â±2 h), 78 h (Â±3 h), 84 h (Â±3 h), 90 h (Â±3 h), and 96 h (Â±3 h) 
o If a subject is asleep, the subject will not be awakened to assess pain. If the subject awakens within the assessment window, a pain score will be collected then. 
o Study staff will be instructed not to complete the NRS pain intensity score af ter any 
physical activity, including the motor block assessment  (for Cohort 1 subjects) . If that 
is not possible, to assess pain intensity at rest, the subject should rest quietly in a supine 
or seated position that does not exacerbate subjectâ€™s postsurgic al pain for 5 -10 minutes 
before assessing the pain score using the NRS.  
â€¢ An unscheduled pain intensity scores (using the NRS) measured as â€œOn a scale from 0 to 10, 
where 0 equals no pain and 10 equals the worst possible pain, how much pain are you experiencing in your operative knee right now ?â€ will be obtained immediately prior to 
administration of any breakthrough pain medication until 96 hours post- surgery  
â€¢ Pain intensity using the NRS at 24 (Â±2 h), 48 (Â±2 h), 72 (Â±2 h), and 96 (Â±3 h) post -surgery,  
measured as â€œOn a scale from 0 to 10, where 0 equals no pain and 10 equals the worst possible 
pain, what was the worst pain in your operative knee in the last 24 hours?â€ 
â€¢ Pain intensity using the NRS at 24 (Â±2 h), 48 (Â±2 h), 72 (Â±2 h), and 96 (Â±3 h) post -surgery,  
measured as â€œOn a scale from 0 to 10, where 0 equals no pain and 10 equals the worst possible pain, what was the average pain  in your operative knee in the last 24 hours?â€ 
Subjects will be instructed to focus all NRS pain intensity ratings on the operative knee, and no other locations where they may be experiencing pain. 
13.1.2. Subject Satisfaction with Postsurgical Pain Control 
Study staff w ill record subject â€™s satisfaction with pain management using 1 question from the 
International Pain Outcome (IPO) questionnaire at 96 hours (Â±3 h) post -surgery. (see Appendix 2, 
Section 18.2).  
13.1.3. Pharmacokinetic Assessments ( Cohort 1 only) 
The blood samples for PK assessment will be obtained from the Cohort 1 subjects. A total of 17 
PK samples will be collected for each subject in Cohort 1. These samples will be obtained at Predose 
(up to 15 min before block), 30 min (Â±5 min), 45 min (Â±5 min), and 1 h (Â±15 min), 2 h (Â±30 min), 
8 h (Â±30 min), 12 h (Â±30 min), 24 h (Â±1 h), 30 h (Â±1 h), 48 h (Â±1 h), 60 h (Â±2 h), 72 h (Â±2 h), 84 h 
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  45 of 68 22 OCT 2021  (Â±2 h), 96 h (Â±3 h), 120 h (Â±3 h), 144 h (Â±3 h), and 168 h (Â±3 h) hours from end of block procedure 
(See Table 2 ). 
13.1.4. Pharmacodynamic Assessments ( Cohort 1 only) 
Pharmacodynamic assessments must be performed by blinded, trained , licensed medical staff (e.g., 
Physician, Registered Nurse, Physician Assistant) and documented on the Investigatorâ€™s study 
Delegation Log. A limited number of study staff (blinded to study drug assignment) should perform 
the sensory/motor assessments. 
Onset and duration of sensory block will be assessed using the light touch assessment sensation to 
characterize the sensory block (see Appendix 3, Section 18.3).  
Onset and duration of motor block will be assessed by active movement of the knee  (knee 
extension) to characterize the motor block (see Appendix 4, Section 18.4) 
13.2. Study Procedures  
13.2.1. Obtaining Informed Consent  
Potential subjects undergoing primary unilateral TKA under spinal anesthesia will be approached 
by the Investigator and/or the study staff for informed consent up to 45 days before the surgery. 
Subject s may be consented on the day of the surgery, if the consent process is started early with 
ample time for the subject to review the informed consent form (ICF) and have all questions answered by the Investigator/study staff prior to providing informed consent. 
13.2.2. Screening  
Subjects may be screened up to 45 days prior to day of surgery but eligibility must be re -confirmed 
on the day of surgery prior to randomization. Screening procedures that are standard of care at the 
institution may be completed prior to written informed consent and documented within the 45-day 
time window.  
The following screening procedures will be performed after the ICF is signed  (if not standard of 
care) :  
â€¢ Assess eligibility  
â€¢ Record medical/surgical history  o As a general guidance, relevant medical/surgical history within the last 5 ye ars (including 
all ongoing history, regardless of start date) should be recorded in the electronic CRF 
(eCRF), with the exception of history that is relevant to the TKA surgery, in which case all years should be recorded. 
o If a siteâ€™s standard process inclu des detailed collection of all history (regardless of 
relevance/age), only the relevant items should be recorded in the eCRF as outlined above; an asterisk or similar indicator can be used in the source documentation to indicate the relevant items that sho uld be included in the eCRF for source data verification purposes. 
â€¢ Record prior medications (in relationship to medical history)  
o Prior medications  taken within 30 days of randomization (including all ongoing 
medications, regardless of start date)  will be r ecorded in the eCRF.   
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  46 of 68 22 OCT 2021  â€¢ Record demographics and baseline characteristics  
â€¢ Record subject height and weight for BMI calculation 
â€¢ Assess chronic opioid use in the past 30 days (average â‰¥30 oral morphine equivalents/day) and 
any use of marijuana (including THC and CBD) in the past 30 days.  
â€¢ Conduct urine pregnancy test for women of childbearing potential 
â€¢ Perform 12 -lead EKG  
â€¢ Record SAEs from the time the ICF is signed 
â€¢ Record medications for treatment of S AEs 
13.2.3. Baseline Procedures (Prior to Study Drug Administration)  
â€¢ On the day of surgery, before  performing  any pain assessments, study staff will review the study 
Pain Rating Guide with the subject. 
â€¢ On the day of surgery, before administration of the block, the study staff  must record responses 
to the following pain assessments: 
o Pain intensity scores (using the NRS) measured as â€œOn a scale from 0 to 10, where 0 
equals no pain and 10 equals the worst possible pain, what was the worst  pain in your 
operative knee in the last 30 days?â€ 
o Pain intensity scores (using the NRS) measured as â€œOn a scale from 0 to 10, where 0 equals no pain and 10 equals the worst possible pain, what was the average pain in your 
operative knee in the last 30 days?â€ 
â€¢ Conduct urine pregnancy test for women of childbearing potential 
â€¢ Conduct urine drug screen 
â€¢ Vital signs will be measured and recorded
 after the subject has rested in a supine position for at 
least 5 minutes  
â€¢ Record changes to concomitant medications since screening  
â€¢ Confirm eligibility and randomize subje ct 
â€¢ Record AEs/ SAEs  
â€¢ For Cohort 1 only: 
o Perform sensory function assessments within 15 minutes before block 
o Perform motor function assessment within 15 minutes before block 
o Obtain blood sample for PK assessment within 15 minutes before block  
13.3. Nerve Block Procedure  
Note: Specific s upplies listed below provided by the Sponsor in the study drug administration kits 
are subject to change based on availability. 
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  47 of 68 22 OCT 2021  13.3.1 Procedures for Adductor Canal Block  
A: Placement of ultrasound probe: 
â€¢ Ensure that the â€œnotchâ€ is positioned on the top left of the ultrasound screen prior to scanning. 
When scanning, have the notched side of the ultrasound probe facing the anterior side of the 
thigh (toward the operator). 
â€¢ With the patient in the supine position, have the subject  bend the operative knee slightly and 
externally rotate the hip.  
â€¢ Place the ultrasound transducer at the midpoint between the inguinal crease and the superior 
pole of the patella , and at the midpoint between the anterior point and posterior point of t he 
thigh. Adjust ultrasound depth as needed. The superficial femoral artery should be visible 
directly beneath the Sartorius muscle  (this scanning and probe placement technique will make 
the top of the ultrasound screen be anatomically â€œmedialâ€ and the bot tom of the screen be 
anatomically â€œ lateralâ€) . 
â€¢ The entry point will be confirmed by locating the point at which the superficial f emoral artery 
is in the middle of the sartorius muscle.  
â€¢ The sartorius muscle, the superficial femoral artery and the vastus medialis muscle are the 
primary ultrasound landmarks for the injection. 
â€¢ The Saphenous nerve is frequently visible as a hyperechoic structure immediately anterior to 
the superficial femoral artery.  
â€¢ Both the nerve to vastus medialis (NVM) and the saphenous nerve will be blocked as both provide innervation to the knee joint. The nerves usually lie between the sartorius muscle and 
the vastus medialis muscle in this scan. The NVM will usually lie more anterior (closer to the 
needle insertion site and away  from the superficial femoral artery and will be encountered first 
with this needle approach. The NVM is not as readily visible, at times, and i s separated from 
the saphenous nerve by a vasto- adductor membrane.  
B: Insertion of needle into adductor canal:  
â€¢ A 100 mm insulated needle will be used connected to a peripheral nerve stimulator (PNS). 
â€¢ From a n anterior/medial in plane  approach, insert the insulated needle within the fascial plane 
between the vastus medialis muscle and the sartorius muscle ( the needle  tip will be going toward 
the superficial  femoral artery ). 
â€¢ This approach will first identify and block the NVM with ultrasound and PNS guidance and subsequently approach and block the saphenous nerve after penetrating the vasto-adductor membrane.  
â€¢ The PNS will be used to help identify both the NVM and the saphenous nerve. 
â€¢ Before entering the needle insertion site, the PNS should be turned to 2 hertz and 0.5 -1,0 mA. 
With a tone change, ensure a circuit has been created. An acceptable evoked response fo r the 
NVM will occur on the medial knee with either potential patellar twitch or distal vastus medialis tendon response. Do not accept direct muscle stimulation if the vastus muscle has been penetrated.  
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  48 of 68 22 OCT 2021  â€¢ Once this is accomplished as described , the approach to the saphenous nerve will continue. 
â€¢ Advance the needle through the vasto- adductor membrane until the tip is just anterior to the 
superficial femoral artery.  
â€¢ Use the same nerve stimulator approach as before to elicit saphenous response. This can be 
parest hesia in the distal medial malleolus or potentially the distal medial knee (infra -patellar 
branch).  Subjects should be asked to report a â€œtappingâ€ or similar sensation on the medial 
leg/medial malleolus.  
â€¢ The injection will occur immediately anterior  to the superficial f emoral artery, below the 
sartorius muscle.  
C: Saline hydrodissection for fascial plane confirmation : 
â€¢ Once the NVM or s aphenous nerve is identified and after careful aspiration, s lowly start the 
saline injection to visualize the NVM or s aphenous nerve so as not to injure it.  
â€¢ The goal is to confirm needle tip position, and no more than 1- 2 mL of saline should be  required. 
â€¢ After saline injection and visual confirmation of the nerve, follow study drug administration as described below (D).  
D: Study drug administration: 
â€¢ Each identified nerve (NVM and saphenous nerve) will receive 10 mL of the study drug. 
â€¢ Slowly start injecting the 10 mL of study drug around each nerve as visualized  during saline 
injection.  This will be a step wise approach as the NVM will be identified first and then the 
saphenous nerve subsequently. 
â€¢ Ultrasound video must be captured from the beginning of hydrodissection until the end of study 
drug administration. The video will be provided to the sponsor within 24 hours from the end of 
block procedure. 
â€¢ Record the start and end time of the adductor canal block. 
13.4. IPACK Infiltration Procedure  
All subjects will receive an IPACK infiltration with 15 mL of 0.25% bupivacaine HCl (37.5 mg) 
immediately followin g study drug administration (should be done with the same set -up for the nerve 
block, prior to surgery). This technique infiltrates local anesthetic in the inter-space between the 
popliteal artery and the posterior capsule of the knee (IPACK) . 
â€¢ With the patient in the supine position, have the subject bend the operative knee slightly and 
externally rotate the hip (as done in adductor canal) . 
â€¢ This will be a medial to lateral technique.  
â€¢ A new 100 mm insulated needle will need to be used. 
â€¢ A liner ultrasound probe can be used (many use a curvilinear probe) and positioned in the 
posterior popliteal fossa. Scanning will occur from caudal to cephalad within the fossa. 
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  49 of 68 22 OCT 2021  â€¢ An adequate depth will be needed to visual the femur anteriorly to the popliteal artery and 
popliteal vein.  
â€¢ From the popliteal fossa, scan cephalad to the popliteal crease where visualization of the femoral condyles can be appreciated anteriorly (or bottom of the ultrasound screen) and the popliteal artery posteriorly (top of ultrasound screen). 
â€¢ The tibial and per oneal nerves may be appreciated posteriorly (top of the screen) to the 
popliteal artery and vein (may be compressed). 
â€¢ Scanning can go slightly more cephalic to the evolution of the femoral shaft (change in bony contour under ultrasound). 
â€¢ Needle insertion will occur on the medial side of the distal thigh and traverse from medial to lateral along the posterior border of the bony landmark under ultrasound guidance. The insertion position can be measured using the cm markings on the ultrasound screen to make 
the insertion site more accurate, this in -plane 90- degree approach will optimize  needle 
visualization.  
â€¢ Infiltration will occur anterior to the popliteal artery posterior to the fe mur. 
â€¢ Record date and start/end time of IPACK infiltration.  
13.5. Post-Block Assessments and Procedures  
The following assessments will be conducted in Cohort 1 subjects only: 
â€¢ Assess sensory and motor function. 
o Perform sensory/motor function assessments at 15 min (Â±5 min), 30 min (Â±5 min), 45 
min (Â±5 min), 1 h (Â±15 min), 2 h (Â±30 min), 8 h (Â±30 min), 12 h (Â±30 min), 24 h (Â±1 h), 
30 h (Â±1 h), 48 h (Â±1 h), 60 h (Â±2 h), 72 h (Â±2 h), 84 h (Â±2 h), 96 h (Â±3 h), 120 h (Â±3 h), 
144 h (Â±3 h), and 168 h (Â±3 h) from the end of the block procedure, or until the sensory/motor function has returned to baseline (pre -dose ) levels. The light touch and 
motor function tests will be rated independently from each other.  
â€¢ Collect scheduled PK blood samples. These samples will be obtained at 30 min (Â±5 min), 45 min (Â±5 min), and 1 h (Â±15 min), 2 h (Â±30 min), 8 h (Â±30 min), 12 h (Â±30 min), 24 h (Â±1 h), 30 h (Â±1 h), 48 h (Â±1 h), 60 h (Â±2 h), 72 h (Â±2 h), 84 h (Â±2 h), 96 h (Â±3 h), 120 h (Â±3 h), 144 h (Â±3 h), and 168 h (Â±3 h) hours from end of block procedure (See Table 2 ).  
In both Cohort 1 and Cohort 2 subjects:  
â€¢ Record AEs/SAEs.  
â€¢ Record concomitant medications.  
13.6. Intraoperative Procedures  
â€¢ Record date and start/end time of spinal anesthesia .  
â€¢ Record intraoperative drugs administered and doses.  
â€¢ Record date and start/end times of surgery .  
â€¢ Record AEs/ SAEs .  
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  50 of 68 22 OCT 2021  â€¢ Record concomitant medications  
13.7. Post-Anesthesia Care Unit (PACU) Procedures  
â€¢ Record date/time of admission to and discharge from the PACU. 
â€¢ Record AEs/ SAEs .  
â€¢ Record concomitant medications . 
â€¢ Record pain intensity scores (using the NRS) measured as â€œOn a scale from 0 to 10, where 0 
equals no pain and 10 equals the worst possible pain, how much pain are you experiencing in your operative knee right now ?â€  will be assessed:  
o Upon arrival in the Post- anesthesia Care Unit (PACU) (Â±5 min)  
o Every 15 minutes in the PACU (Â±5 min) 
o At PACU discharge (Â±5 min) 
â€¢ Record an unscheduled pain intensity score (using the NRS) measured as â€œOn a scale from 0 to 
10, where 0 equals no pain and 10 equals the worst possible pain, how much pain are you experiencing in your operative knee right now ?â€ immediately prior to  administration  of any 
breakthrough pain medication. 
â€¢ Record date, time, and dosage of any breakthrough pain medication.  
â€¢ Measure and record vital signs as follows: 
o Upon arrival in the PACU (Â±5 min)  
o At PACU discharge (Â±5 min) 
      
â€¢ For Cohort 1 subjects only (See Table 2 ): 
o Collect scheduled PK blood sample(s).  
o Perform sensory and motor function assessments. 
13.8. Postsurgical Assessments from End of Surgery through Discharge  
â€¢ Record pain intensity scores (using the NRS) measured as â€œOn a scale from 0 to 10, where 0 
equals no pain and 10 equals the worst possible pain, how much pain are you experiencing in your operative knee right now ?â€ will be assessed:  
o Every 6 hours from the end of surgery until 96 hours post -surge ry: 6 h (Â±2 h), 12 h 
(Â±2 h), 18 h (Â±2 h), 24 h (Â±2 h), 30 h (Â±2 h), 36 h (Â±2 h), 42 h (Â±2 h), 48 h (Â±2 h), 54 
h (Â±2 h), 60 h (Â±2 h), 66 h (Â±2 h), 72 h (Â±2 h), 78 h (Â±3 h), 84 h (Â±3 h), 90 h (Â±3 h), 
and 96 h (Â±3 h). 
o If a subject is asleep, the subject will not be awakened to assess pain. If the subject 
awakens within the assessment window, a pain score will be collected then. 
o Study staff will be instructed not to complete the NRS pain intensity score after any physical activity, including the motor block ass essment  (for Cohort 1 subjects) . If 
that is not possible, to assess pain intensity at rest, the subject should rest quietly in 
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  51 of 68 22 OCT 2021  a supine or seated position that does not exacerbate subjectâ€™s postsurgical pain for 
5-10 minutes before assessing the pain score using the NRS. 
â€¢ Record an unscheduled pain intensity score (using the NRS) measured as â€œOn a scale from 0 to 10, where 0 equals no pain and 10 equals the worst possible pain, how much pain are you experiencing in your operative knee right now ?â€ immediately prior to administration of any 
breakthrough pain medication until 96 hours post- surgery . 
â€¢ Record p ain intensity scores ( using the NRS ) at 24 (Â±2 h), 48 (Â±2 h), 72 (Â±2 h), and 96 (Â±3 h) 
post- surgery,  measured as â€œOn a scale from 0 to 10, where 0 equals no pain and 10 equals the 
worst possible pain, what was the worst  pain in your operative knee in the last 24 hours?â€ 
â€¢ Record p ain intensity scores ( using the NRS ) at 24 (Â±2 h), 48 (Â±2 h), 72 (Â±2 h), and 96 (Â±3 h) 
post- surgery,  measured as â€œOn a scale from 0 to 10, where 0 equals no pain and 10 equals the 
worst possible pain, what was the average  pain in your operative knee in the last 24 hours?â€ 
â€¢ Record subjectâ€™s satisfaction with pain management using 1 question from the International Pain Outcome ( IPO) questionnaire at 96 hours (Â±3 h) post-surgery.  
â€¢ Record AEs/ SAEs.  
â€¢ Record concomitant medications.   
â€¢ Record vital si gns (i.e., blood pressure, pulse, respiratory rate, oxygen saturation, and body 
temperature)  after the subject has rested in a supine position for at least 5 minutes . See Table 1 
â€¢ Perform  12-lead EKG. See Table 1  
â€¢ For Cohort 1 subjects only: (See Table 2): 
o Collect scheduled PK blood sample(s).  
o Perform sensory and motor function assessments. 
Postoperatively the subject will progress to full weight bearing as tolerated per the surgeonâ€™s 
standard of care. A walker is recommended for physical therapy until the fall risk is minimized and the subject can transfer and ambulate safely . 
13.9. Health Care Facility Discharge  
â€¢ Subjects in Cohort 1 and Cohort 2 will be discharged after the completion of the 168 h and 96 h 
assessments, respectively.  
â€¢ Record date and time of health care facility discharge.  
13.10.  Unscheduled Visits  
â€¢ If a sensory or motor function deficit persists on POD 7 (168 h post -surgery), the subject is to 
return for unscheduled visit(s) at the Investigator's discretion through POD 14 or until the sensory or motor function has returned to baseline, whichever occurs first.  
â€¢ Record concomitant medications including all analgesic medication.  
â€¢ Record AEs/SAEs.  
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  52 of 68 22 OCT 2021  13.11.  Postsurgical Day 14  Follow-up Phone Call 
â€¢ Ask the subject about any new AE(s) and the resolution of any ongoing adverse event(s) since 
discharge. Record any adverse event information. 
â€¢ Ask the subject about any medication(s) taken since discharge from the health care facility. 
14. ADVERSE EVENT REPORTING  
Consistent with the current regulatory guidance provided by the US FDA CFR Part 312 and the ICH GCP, AE  and SAE are defined in Section 14.1.1 and Section 14.2.1, respectively.   
The concepts of AEs and SAEs represent regulatory instruments used to evaluate and monitor the safety of clinical study subjects.  Therefore, these terms only apply in light of their regulatory 
definition.  The term serious, in a regulatory sense, does not necessarily mean severe.  The SAE 
concept is used primarily to identify, during the conduct of the study, those SAEs that may require 
expedited reporting to regulatory authorities. 
14.1. Adverse Events   
14.1.1. Definitions  
Adverse Event ( AE): Any untoward medical occurrence associated with the use of a drug in 
humans, whether or not considered drug related. An AE (also referred to as an adverse experience) can be any unfavorable and unintended sign (e.g., abnormal laboratory finding), symptom, or 
disease temporally associated with the use of a drug, without any judgment about causality. An AE 
can arise from any use of the drug (e.g., off -label use in combination with another drug) and from 
any route of administration, formulation, or dose, including an overdose.  
An AE can be any unfavorable and unintended change in a body structure or body function. Adverse events include any clinically significant deterioration of a subjectâ€™s medical status. The AE may 
involve any organ or system and can be represented by the new onset or deterioration of a disease, a syndrome, a symptom, a physical sign, as well as by findings and results of instrumental 
examinations and laboratory tests. Any medically relevant and untoward change after the subject 
signs the ICF, including frequency or pattern changes for a fluctuating condition (e.g., migraine) is considered an AE.  
An AE that occurs after the administration of the study treatment is considered a treatment-
emergent adverse event (TEAE).  
Adverse Reaction : Any AE caused by a drug. Adverse reactions are a subset of all suspected adverse 
reactions for which there is reason to conclude that the drug caused the event.  
Suspected Adverse Reaction : Any AE for which there is a reasonable possibility that the drug 
caused  the AE. A suspected adverse reaction implies a lesser degree of certainty about causality 
than adverse reaction, which means any AE caused by a drug. Suspected adverse reactions are a subset of all AEs for which there is a reasonable possibility that the drug caused the event.  
14.1.2. Recording Adverse Events  
It is the responsibility of the Investigator to document all AEs with an onset after the subject  is 
randomized and SAEs with an onset after the subject  signs the ICF. For the purpose of this study, 
all AEs th at occur through POD 14 must be recorded regardless of whether or not they are 
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  53 of 68 22 OCT 2021  considered related to study drug. Any AEs occurring after POD 14 only need to be reported if 
considered related to study drug by Investigator. Whenever feasible, AE terms must be documented 
as medical diagnoses (highest possible level of integration); otherwise, the AEs must be reported 
separately as individual signs or symptoms. Only one AE per record  should be recorded in the AE 
CRF; for example, an AE of nausea and vomiting would be listed as two separate events: the event of nausea and the event of vomiting. If a diagnosis is established after symptoms are recorded on the AE CRF, the diagnosis must be recorded, and the symptoms removed . Whenever possible, 
abnormal laboratory results must be reported as their clinical corollary (e.g., low potassium should be recorded as hypokalemia).  
A continuous AE with varying grades of severity must be recorded as one AE. The highest grade 
of severity experienced by that subject during the course of the continuous AE must be recorded.  
Any condition noted before the subject signs the ICF will be listed as Medical History (this include s 
conditions prior to randomization)  and is considered a pre -existing condition. If a pre -existing 
condition c hanges (i.e., becomes more severe or more frequent) at any time after the ICF is signed, 
or after randomization, it is considered an AE. Note: A change in treatment for a pre -existing 
condition (e.g., new high blood pressure medication), does not necessarily indicate an AE.  Information recorded on the AE CRF will include the AE term, the date and time of onset, severity, 
seriousness, relationship to study drug, action taken with subject due to AE, and the outcome of the AE, including the date and time of resolution, if  applicable.   
14.1.3. Severity of Adverse Events  
In general, the severity of an AE should be categorized using the following guidelines:  
Mild : An AE that is easily tolerated by the subject, causing minimal discomfort and not 
interfering with everyday activities.  
Moderate: An AE that is discomforting and interferes with normal everyday activities.  
Severe: An AE that prevents normal everyday activities. 
The term "severe" is often used to describe the intensity (severity) of a specific event (as in mild, 
moderate, or severe myocardial infarction); the event itself, however, may be of relatively minor medical significance (such as severe headache).  This is not the same as "serious," which is based 
on subject /event outcome or action criteria usually associated with events that pose a threat to a 
subject 's life or functioning.  Seriousness (not severity) serves as a guide for defining regulatory 
reporting obligations. 
14.1.4. Relationship of Adverse Events to Study Drug  
The Investigator will assess the relationship of the AE to study drug after careful medical 
consideration on a case -by-case basis.  General guidelines for determining the causality of an AE 
to the study drug are provided below: 
Unrelated : A causal relationship between the study drug and the AE can be easily ruled out 
(e.g., based on the temporal sequence, absence of a reasonable pathophysiological 
mechanism, or direct evidence of actual cause).  
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  54 of 68 22 OCT 2021  Unlikely :  A clinical event with a temporal relationship to study drug administration which 
makes a causal relationship improbable and in which other drugs, chemicals, or 
underlying disease provide a plausible explanation. 
Possible: A clinical event with a reasonable time sequence to administration of the study drug 
but which could also be explained by a concurrent disease or other drugs or chemicals . 
Probable: A clinical event with a reasonable time sequence to administration of the study drug 
unlikely to be attributed to a concurrent disease or other drugs or chemicals and which follows a clinically reasonable response on withdrawal (dechallenge) . 
Definite:  The pharmacological properties of the study drug(s) or of the substance class, and 
the course of the  AE after dechallenge and, if applicable, after rechallenge, and/or 
specific test indicate involvement of the study drug(s) in the occurrence/worsening of the AE , and no indication of other causes exists. 
14.1.5. Outcome of Adverse Events  
The Investigator will ass ess the outcome of the AE after careful medical consideration, on a 
case-by-case basis.  General guidelines are provided below: 
Recovered/Resolved:  The event resolved and the subject recovered from the AE.  
Recovered/Resolved  
with Sequelae:  The initial event resolved but has a continuing abnormal condition 
as a result of the AE.  
Not Recovered/  
Not Resolved: At the time of the last assessment, the event was ongoing, with an 
undetermined outcome. Note: ongoing AEs are not to be considered resolved  as a result of death.  
Recovering/Resolving:  At the time of the last assessment, the event was decreasing in 
frequency, severity, etc., and a resolution was expected. 
Fatal:  The AE directly caused death.  
Unknown:  There was an inability to access the sub ject or the subjectâ€™s rec ords 
to determine the outcome (e.g., subject withdrew consent or was lost to follow-up). 
14.1.6. Action Taken with Subject Due to  an Adverse Event  
The Investigator will provide any actions taken regarding the subject (e.g., treatment, diagnostic 
tests, laboratory tests, or therapy) for each reported AE. 
â€¢ None. 
â€¢ Medication.  
â€¢ Non-pharmaceutical therapy ( the specific therapy used must be recorded in the CRF). 
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  55 of 68 22 OCT 2021  â€¢ Discontinued from study. 
â€¢ Other ( the specific action taken must be recorded in the CRF). 
14.1.7. Adverse Events of Special Interest   
Based on review of all peripheral nerve blocks, the following conditions will be considered to be 
adverse events of special interest upon review of the AEs:  
â€¢ Fall 
â€¢ Persistent1 tingling  
â€¢ Persistent1 numbness  
â€¢ Persistent1 weakness  
â€¢ Hypersensitivity  
â€¢ Seizures  
â€¢ Tremors  
â€¢ Dizziness  
â€¢ Hematoma formation  
â€¢ Cardiovascular depression  
â€¢ Dyspnea  
â€¢ Cardiovascular arrest  
â€¢ Altered sensorium  
â€¢ Visual disturbances  
â€¢ Local anesthetic systemic toxicity  (LAST)  
1 Persistent : Any conditions (e.g., tingling, numbness, or sensory/motor  weakness  affecting the 
nerve block region, after the study drug administration) that persists for greater  than 168 hours  from  
the time of  onset.  
In case an AE of special interest (AESI) or serious AE (SAE) occurs during the study, if the 
investigator or medical monitor considers that the event may be related to study treatment or suggests the possible occurrence of local anesthetic systemic toxicity (LAST; with or without the 
need for treatm ent [e.g., intralipids]), an unscheduled PK blood sample, 12- lead EKG, and vital 
signs must be collected. Neurological assessments will be conducted according to the study siteâ€™s 
standard of care at least once daily until resolution of symptoms. 
Investigat ors, study coordinators, and patient study assessors will be trained on adverse event 
ascertainment in general, with a special focus directed to signs and symptoms that may represent 
evidence of systemic toxicity. All AEs of special interest will be manage d per standard of care and 
should be reported to the M edical Monitor and recorded in the database. 
3DFLUD3KDUPDFHXWLFDOV,QF   &$GGXFWRU&DQDO%ORFN
(;3$5(/ÂŠ  &OLQLFDO6WXG\3UR WRFRO$PHQGPHQW

 
&21),'(17,$/ RI 2&76HULRXV$GYHUVH(YHQWV
'HILQLWLRQRID6HULRX V$GYHUVH(YHQW
6HULRXV$GYHUVH(YHQW6$($Q$(RUVXVSHFWHGDGYHUVHUHDFWLR QLVFRQVLGHUHGÂ³VHULRXVÂ´LILQ
WKHYLHZRIHLWKHUWKH,QYHVWLJ DWRURU6SRQVRULWUHVXOWVLQD Q\RIWKHIROORZLQJRXWFRPHV
x'HDWK
x$OLIHWKUHDWHQLQJDGYHUVHHYHQW
x,QSDWLHQWKRVSLWDOL]DWLRQRUSU RORQJDWLRQRIH[LVWLQJKRVSLWDOL ]DWLRQ
x$SHUVLVWHQWRUVLJQLILFDQWLQFDSDFLW\
x&RQJHQLWDODQRPDO\ELUWKGHIHFW
x0HGLFDOO\VLJQLILFDQW
'HDWK$Q\HYHQWUHVXOWLQJLQDVXEMHFWÂ¶VGHDWKPXVWEHUHSRUWHGDVDQ 6$(+RZHYHUGHDWKLQ
DQGRILWVHOILVQRWDQ$(LWLVDQRXWFRPH7KHFDXVHRIGH DWKLVWKH$(7KHUHIRUHWKH
,QYHVWLJDWRUVKRXOGPDNHHYHU\HIIRUWWRREWDLQDQGGRFXPHQWWK HFDXVHRIGHDWKIRUDOOVXEMHFWV
ZKRGLHGXULQJWKHVWXG\,IGHVSLWHDOOHIIRUWVWKHFDXVHR IGHDWKUHPDLQVXQNQRZQWKH$(VKRXOG
EHGRFXPHQWHGDVDQÂ³XQVS HFLILHGIDWDOHYHQWÂ´
/LIHWKUHDWHQLQJ $Q$(LVFRQVLGHUHGOLIHWKUHDWHQLQJLILQWKHYLHZRIHLWKHU WKH,QYHVWLJDWRURU
VSRQVRULWVRFFXUUHQFHSODFHVWKH VXEMHFWDWLPPHGLDWHULVNRI GHDWK,WGRHVQRWLQFOXGHDQ$(
WKDWKDGLWRFFXUUHGLQDPRUHVH YHUHIRUPPLJKWKDYHFDXVHG GHDWK
+RVSLWDOL]DWLRQ ,WVKRXOGEHQRWHGWKDWKRVSLWDOL]DWLRQLQDQGRILWVHOIGR HVQRWUHSUHVHQWDQ6$(
,WLVWKH$(OHDGLQJWRWKHVXEMHFWÂ¶VKRVSLWDOL]DWLRQWKDWEHFR PHVÂ³VHULRXVÂ´ZKHQLWUHTXLUHVLQSDWLHQW
FDUH&RQVHTXHQWO\DQ6$(VKRXOGQRWEHUHSRUWHGLQFDVHRIS UHSODQQHGKRVSLWDOL]DWLRQVIRUD
SUHH[LVWLQJFRQGLWLRQWKDWGLGQRWZRUVHQGXULQJWKHVWXG\+ RZHYHUDQ\PHGLFDOFRQGLWLRQWKDW
GHOD\VDVXEMHFWÂ¶VGLVFKDUJHIUR PWKHKRVSLWDOLHSURORQJHG KRVSLWDOL]DWLRQRUUHTXLUHVWKHVXEMHFW
WREHUHDGPLWWHGVKRXOGEH UHSRUWHGDVDQ6$( 
3HUVLVWHQWRUVLJQLILFDQWLQFDSDFLW\ $VXEVWDQWLDOGLVUXSWLRQRI DSHUVRQÂ¶VDELOLW\WRFRQGXFW
QRUPDOOLIHIXQFWLRQV
&RQJHQLWDODQRPDO\ELUWKGHIHFW 5HSRUWLI\RXVXVSHFWWKDWH[SRVXUHWRDPHGLFDOSURGXFWSULR U
WRFRQFHSWLRQRUGXULQJSUHJQDQF\P D\KDYHUHVXO WHGLQDQDGYHU VHRXWFRPHLQWKHFKLOG
0HGLFDOO\6LJQLILFDQW ,PSRUWDQWPHGLFDOHYHQWVWKDW PD\QRWUHVXOWLQGHDWKEHOLIH WKUHDWHQLQJ
RUUHTXLUHKRVSLWDOL] DWLRQPD\EHFRQVLGHUHGVHULRXVZKHQEDV HGXSRQDSSURSULDWHPHGLFDO
MXGJPHQWWKH\PD\MHRSDUGL]HWK HVXEMHFWDQGPD\UHTXLUHPHGLF DORUVXUJLFDOLQWHUYHQWLRQWR
SUHYHQWRQHRIWKHRXWFRPHVOLV WHGLQWKLVGHILQLWLRQ([DPSOH VRIVXFKPHGLFDOO\VLJQLILFDQWHYHQWV
LQFOXGHDOOHUJLFEURQFKRVSDVPUHTXLULQJLQWHQVLYHWUHDWPHQWLQ DQ(PHUJHQF\'HSDUWPHQWRUDW
KRPH EORRG G\VFUDVLDV RU FRQYXOVLRQVWKDW GR QRW UHVXOWLQ LQS DWLHQWKRVSLWDOL ]DWLRQ RUWKH
GHYHORSPHQWRIGUXJGHS HQGHQF\RUGUXJDEXVH 
5HSRUWLQJ6HULRXV$GYHUVH(YHQWV
$Q\6$(RUGHDWKWKDWRFFXUVDWDQ\WLPHDIWHUWKHVXEMHFWVLJQ VWKH,&)WKURXJK'D\ZKHWKHU
RUQRWUHODWHGWR(;3$5(/PXVWEHUHSRUWHGE\WKH,QYHVWLJDWRU RUGHVLJQHHWR3DFLUD'UXJ6DIHW\
ZLWKLQ  KRXUV RI GLVF RYHU\ E\ HLWKHU HPDLO   DQG CCI
3DFLUD3KDUPDFHXWLFDOV,QF   &$GGXFWRU&DQDO%ORFN
(;3$5(/ÂŠ  &OLQLFDO6WXG\3UR WRFRO$PHQGPHQW

 
&21),'(17,$/ RI 2&7RUID[ ,QDGGLWLRQWKH,QYHVWLJDWRURUGHVLJQHHLV
HQFRXUDJHGWRFRQWDFWWKH0HGLFDO 0RQLWRUWRGLVFXVVWKHFDVH DVQHHGHG
,QYHVWLJDWRUVVKRXOGQRWZDLWWRUHFHLYHDGGLWLRQDOLQIRUPDWLRQ WRIXOO\GRFXPHQWWKHHYHQWEHIRUH
QRWLI\LQJ3DFLUD'UXJ6DIHW\RUGHVLJQHHRIWKH6$(7KHID[R UHPDLOUHSRUWVKRXOGEHIROORZHG
E\DIXOOZULWWHQVXPPDU\XVLQJWKH6$()RUPGHWDLOLQJUHOHYDQW DVSHFWVRIWKH6$(LQTXHVWLRQ
:KHUHDSSOLFDEOHLQIRUPDWLRQIURPUHOHYDQWKRVSLWDOUHFRUGVDQ GDXWRSV\UHSRUWVVKRXOGEH
REWDLQHGDQGDOOVXEMHFWLGHQWLI \LQJLQIRUPDWLRQUHGDFWHGSULRU WRIRUZDUGLQJWR3DFLUD,QWKHHYHQW
RIDIDWDORUOLIHWKUHDWHQLQJ6$(DQ\UHTXLUHGIROORZXSPXVW EHSURYLGHGWR3DFLUD'UXJ6DIHW\
RUGHVLJQHHLPPHGLDWHO\7KH,QYHVWLJDWRUZLOOIROORZDOO6$(V XQWLOUHVROYHGRUWKHFRQGLWLRQ
VWDELOL]HVDQGIXUWKHUIRO ORZXSLVQRWZDUUDQWHG
,IWKH,QYHVWLJDWRULVPDGHDZDUHRIDQ\6$(VDIWHU'D\WKH VHVKRXOGDOVREHUHSRUWHGWR3DFLUD
'UXJ6DIHW\RUGHVLJQHHSURYLGHG WKH6$(LVFRQVLGHUHGUHODWHG WR(;3$5(/7KHVLWHZRXOG
WKHQSURYLGHDFRPSOHWHG6$(IRUPZLWKLQEXVLQHVVGD\DQGWKH HYHQWZRXOGEHIROORZHGXQWLO
UHVROXWLRQRUXQWLODGHTXDWH VWDELOL]DWLRQLVPHW
67$7,67,&$/0(7+2'6
$FRPSUHKHQVLYHVWDWLVWLFDODQDO\VLVSODQ6$3ZLOOEHGHYHORS HGDQGVLJQHGRIIIRUWKLVVWXG\
SULRUWRWKHGDWDED VHORFNXQEOLQGLQJ
6WXG\+\SRWKHVLV
7KHSULPDU\QXOODQGDOWH UQDWLYHK\SRWKHVLVLV
x+(;3$5(/DGPL[DUPLVQRWGLIIHUHQWIURPEXSLYDFDLQH+&ODUPZ LWKUHVSHFWWRWKH$8&
RIWKH156SDLQLQWHQVLW\V FRUHVIURPWRKRXUVSRVWVXUJHU \
x+D(;3$5(/DGPL[DUPLVOHVVWKDQEXSLYDFDLQH+&ODUPZLWKUHV SHFWWRWKH$8&RIWKH
156SDLQLQWHQVLW\VFRUHV IURPWRKRXUVSRVWVXUJHU\
6WXG\(QGSRLQWV 
7KHHQGSRLQWVWREHDVVHVVHGLQWKLVVWXG\DUHOLVWHGLQ 6HFWLRQ (IILFDF\(QGSRLQWV 6HFWLRQ
6DIHW\ (QGSRLQWV 6HFWLRQ   3KDUPDFRNLQHWLF (QGSRLQWV DQG 6HFWLRQ 
3KDUPDFRG\QDPLF(QGSRLQWV
'HWHUPLQDWLRQRI6DPSOH6L]H
7KHWRWDOVDPSOHVL]HIRU&RKRU WDQG&RKRUWZDVFDOFXODWHG EDVHGRQWKHSULPDU\RXWFRPH
PHDVXUHRI156SDLQLQWHQVLW\VFRUHV$WRWDOVDPSOHVL]HRI VXEMHFWVUDQGRPL]DWLRQ
(;3$5(/DGPL[%XSLYDFDLQH+&OSURYLGHVDWOHDVWSRZHU WRGHWHFWDWUHDWPHQW
GLIIHUHQFHRIXQLWVLQWKH$8& V6' FRPSDULQJ(;3$5(/D GPL[DUPZLWK%XSLYDFDLQH
+&ODUPDWRQHVLGHGVLJQLILFDQFHOHYHO
$QDO\VLV3RSXODWLRQV
7KHIROORZLQJVWXG\SRSXODWLRQVDUHSODQQHG
x(IILFDF\SRSXODWLRQZLOOFRQVLV WRIDOOUDQGRPL]HGVXEMHFWVZKR UHFHLYHWKHVWXG\GUXJXQGHUJR
WKHSODQQHGVXUJHU\DQGKDYHD WOHDVWRQHSRVWVWXG\GUXJDGPL QLVWUDWLRQ156SDLQDVVHVVPHQW
$OODQDO\VHVZLOOEHEDVHGRQUDQGR PL]HGWUHDWPHQWUHJDUGOHVVR IDFWXDOWUHDWPHQWUHFHLYHGCCI CCI
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  58 of 68 22 OCT 2021  â€¢ Safety  population will consist of all randomized subjects who received study drug.  All analyses 
will be based on actual treatment received.  
â€¢ PK population will consist of all randomized  subjects  in Cohort 1  who receive study drug and 
provide sufficient samples to enable calculation of PK parameters.  
â€¢ PD population will consist of  randomized subjects  in Cohort 1 who receive study drug and 
provide sufficient data to allow for calculation of PD parameters required for analysis. 
15.5. Handl ing Subject Dropouts and Discontinuations  
 Methods for dealing with missing data for other endpoints will be described in the SAP. 
15.6. Statistical Analyses  
Continuous variables will be summarized using descriptive statistics (n [number of subjects 
contributing data], mean, SD, median, minimum, and maximum). Categorical variables will be tabulated (n and percentage) by category. 
15.6.1. Baseline Characteristics  
Baseline characteristics will be summarized or tabulated as appropriate.  
15.6.2. Efficacy Analyses 
All eff icacy endpoint analyses will be conducted using the efficacy population.  
The primary efficacy analysis endpoint is AUC of NRS pain intensity scores from 0- 96 hours post -
surgery, and it will be analyzed using ANCOVA model with treatment as a main effect. A dditional 
covariates may be included. EXPAREL  admix arm will be compared to Bupivacaine HCl arm. 
Based on the model, the least squared mean (LSM) difference between EXPAREL  admix  arm and 
Bupivacaine HCl arm  will be estimated  with 95% confidence interval. 
Total postsurgical opioid consumption in oral morphine equivalents (OMED) from 0 to 96 hours 
will be summarized by treatment arm and overall. To test the difference between the EXPAREL 
admix arm  and Bupivacaine HCl arm , an ANCOVA model will be used. Time to first postsurgical 
opioid medication will be analyzed using the Kaplan- Meier survival method. Worst and average 
NRS pain intensity scores through 24h, 48h, 72h, and 96h from the end of surgery will be 
summarized by treatment arm  and overall. 
Summary statistics (n, mean, median, standard deviation, minimum, maximum) will be shown for each continuous measure of efficacy by treatment arm and overall. Number and percentage of 
subjects in each category will be shown for each categorical measure of efficacy by t reatment arm 
and overall. 
All assessments will be listed in by -subject data listing.  
15.6.3. Safety Analyses 
All safety analyses will be based on the safety population. 
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  59 of 68 22 OCT 2021  Adverse event verbatim terms will be mapped to preferred terms and related system organ class 
using the Medical Dictionary for Regulatory Activities (MedDRA). Events that start prior to the 
start of study drug administration will be identified in a by- subject listing. Incidence rates of TEAEs 
and the proportion of subject s prematurely withdrawn from the study due to a TEAE will be shown 
for each treatment arm. Incidence rates will also be displayed for each treatment arm for TEAEs by 
severity and separately by relationship. If severity of an AE is not reported, then for tables of AEs by severity, the event will be classified as â€˜Severeâ€™ and will be footnoted for the table to indicate this imputation. If relationship to study drug is not reported for an AE, then for tables of study-drug related AEs, the event will be assigned the relationship of  â€˜definite .â€™ Incidence rates of SAEs will 
also be shown for each treatment arm. All incidence rates will be categorized and displayed by 
system organ class and preferred term.  
15.6.4. Pharmacokinetic Analysis  
Pharmacokinetic parameters will be estimated from the P K analysis set, using plasma drug 
concentration -time profiles, where appropriate, by non- compartmental analysis.  
 Actual sampling time will be used for all calculations of the PK parameters. If there is any doubt in the actual time a sample was taken, then the scheduled time will be used.   Descriptive statistics will be used to summarize the PK parameters.  
15.7. Significance Testing  
Unless specified otherwise, all statistical tests will be 1 -sided at alpha=0.025 level. 
15.8. Interim Analysis  
An unblinded interim analysis will occur when a total of approximately 80 subjects (40 in each 
arm) combined from Cohort 1 and Cohort 2 have enrolled with complete assessment data for the 
primary efficacy outcome. The efficacy will be evaluated and compared between study arms. Primary purpose of this interim analysis is to evaluate the sample size assumptions and evaluate 
futility. Full details on the planned or additional interim analysis will be covered in a prospective 
interim analysis plan . 
 
 
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  60 of 68 22 OCT 2021  16. REFERENCES 
American Society of Anesthesiologists Task Force on Pain Management. Practice guidelines 
for acute pain management in the postoperative setting: A report by the American Society 
for Anesthesiologist Task Force on Pain Management Acute Pain Section. Anesthesiology.  
1995;82:1071âˆ’ 1081. 
Apfelbaum JL, Chen C, Mehta SS, et al. Postoperative pain experience: Results from a national survey suggests postoperative pain continues to be undermanaged. Anesth Analg. 
2003;97:535âˆ’ 540. 
Breivik H, Hogstrom H, Niemi G , et al.  Safe and effective post -operative pain relief: introduction 
and continuous quality- improvement of comprehensive post -operative pain management programs. 
BailliÃ©reâ€™s Clin Anaesthesiol. 1995a;9:423â€“460. 
Breivik H. Benefits, risks and economics of post -operative pain management programs. BailliÃ¨reâ€™s 
Clin Anaesthesiol . 1995b;9:403â€“422. 
Carr DB, Goudas LC. Acute pain. Lancet . 1999;353: 2051â€“2058. 
Dahl V, Raeder JC. Non- opioid postoperative analgesia. Acta Anaesthesiol Scand. 2000;44:1191â€“
203. 
EXPAREL Full Presc ribing Information, March  2021. 
EXPAREL Investigatorâ€™s Brochure, Edition 23, 21 October  2021. 
Marks RM, Sacher EJ. Under treatment of medical inpatient pain with narcotic analgesics. 
Ann Intern Med . 1973;78:173â€“181. 
Oderda GM, Said Q, Evans RS, et al. Opioid- related adverse drug events in surgical 
hospitalizations: Impact on cost and length of stay. Ann Pharmacother . 2007;41(3):400âˆ’ 406. 
Papper EM, Brodie BB, Rovenstein EA. Postoperative pain: its use in the comparative evaluation 
of analgesics. Surgery . 1952;32:107â€“109. 
Perkins FM, Kehlet H. Chronic pain as an outcome of surgery. A review of predictive factors. Anesthesiology . 2000;93:1123â€“33. 
Petersen -Felix S, Curatolo M. Neuroplasticity â€” an important factor in acute  and chronic pain. 
Swiss Med Weekly. 2002;132:273â€“278. 
Rothaug J, Zaslansky R, Schwenkglenks M, et al. Patientsâ€™ perception of postoperative pain 
management: validation of the International Pain Outcomes (IPO) questionnaire. J Pain. 2013; 14(11), 1361â€“1370. 
Schug SA, Large RG. Economic considerations in pain management. Pharmacoeconomics . 
1993;3:260â€“7;9.  
Stephen J, Laskin C, Pashos B et al. The burden of acute postoperative pain and the potential role 
of the COX-2- specific inhibitors. Rheumatology . 2003;42(3): iii40â€“iii52.    
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  61 of 68 22 OCT 2021  17. INVESTIGATOR AGREEMENT  
 
Printed Name of Investigator:  
 Printed Title/Position:  
   
I have reviewed this protocol (including a ppendices) and agree:  
â€¢ To assume responsibility for the proper conduct of the study at this site; 
â€¢ To conduct the study in compliance with this protocol, with any future amendments, and 
with any other study conduct procedures provided by Pacira Pharmaceuticals, Inc.  or 
designee.  I also agree to comply with Good Clinical Practice and all regulatory 
requirements;  
â€¢ Not to implement any changes to the protocol without agreement from Pacira 
Pharmaceuticals, Inc.  or designee and prior review and written approval from the 
Independent Ethics Committee, except where it is necessary to eliminate an immediate hazard to the subjects or for administrative aspects of the study (where permitted by applicable regulatory requirement s);  
â€¢ That I am thoroughly familiar with the appropriate use of the investigational product(s), as described in this protocol, and with other relevant information ( e.g., the Investigatorâ€™s 
Brochure);  
â€¢ To ensure that all persons assisting me with the conduct of this study are adequately informed about the investigational product(s) and about their study- related duties and 
functions as described in this protocol; 
â€¢ That I am aware that regulatory authorities may require Investigators to disclose all 
information about significant ownership interests and/or financial ties related to the sponsor 
and/or the investigational product(s).  Consequently, I agree to disclose all such significant financial information to Pacira Pharmaceuticals, I nc. and to update this information 
promptly if any relevant changes occur during the course of the study through 1 year following completion of the study.  I also agree that any information regarding my 
significant financial interest related to Pacira Pharmaceuticals, Inc.  and/or the 
investigational product(s) will be disclosed to the regulatory authorities by Pacira 
Pharmaceuticals, Inc.  
 
  ____________________________________ _____________________________ 
Signature of Investigator    Date   
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  62 of 68 22 OCT 2021  18. APPENDICES  
  
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  63 of 68 22 OCT 2021  18.1. Appendix 1: Pain Intensity Scores using the Numeric Rating Scale 
(NRS)  
Pain intensity will be measured using the 11- point NRS. The study staff will record the subjectâ€™s  
pain on a scale of 0 (no pain) to 10 (worst possible pain). Subjects will be instructed  to focus all 
NRS pain intensity ratings on the operative knee , and not other locations where they may be 
experiencing pain. 
â€¢ Pain intensity scores ( using the NRS ) measured as â€œOn a scale from 0 to 10, where 0 equals 
no pain and 10 equals the worst possible  pain, what was the worst  pain in your operative 
knee in the last 30 days?â€ and â€œOn a scale from 0 to 10, where 0 equals no pain and 10 
equals the worst possible pain, what was the average  pain in your operative knee in the last 
30 days?â€ will be assessed at D ay of surgery  (prior to surgery).  
â€¢ Pain intensity scores ( using the NRS ) measured as â€œOn a scale from 0 to 10, where 0 equals 
no pain and 10 equals the worst possible pain, how much pain are you experiencing in your 
operative knee right now ?â€  will be assessed:  
âˆ’ Upon arrival in the PACU (Â±5 min) 
âˆ’ Every 15 minutes in the PACU (Â±5 min) 
âˆ’ At PACU discharge  (Â±5 min)  
âˆ’ Every 6 hours from the end of surgery until 96 hours post -surgery: 6 h (Â±2 h), 12 h (Â±2 
h), 18 h (Â±2 h), 24 h (Â±2 h), 30 h (Â±2 h), 36 h (Â±2 h), 42 h (Â±2 h), 48 h (Â±2 h), 54 h (Â±2 
h), 60 h (Â±2 h), 66 h (Â±2 h), 72 h (Â±2 h), 78 h (Â±3 h), 84 h (Â±3 h), 90 h (Â±3 h), and 96 h 
(Â±3 h) 
âˆ’ If a subject is asleep, the subject will not be awakened to  assess pain. If the subject 
awakens within the assessment window, a pain score will be collected then 
âˆ’ Study staff  will be instructed not to complete the NRS pain intensity score after any 
physical activity, including the motor block assessment  (for Cohort  1 subjects) . If that 
is not possible, to assess pain intensity at rest, the subject should rest quietly in a supine or seated position that does not exacerbate his or her postsurgical pain for 5-10 minutes before entering the pain score using the NRS . Subjects will also be required to provide 
unscheduled pain assessments prior to consumption of any breakthrough pain medication  
âˆ’ An unscheduled NRS assessment will be obtained immediately prior to administration of any breakthrough pain medication until 96 hours post- surgery   
â€¢ Pain intensity scores ( using the NRS) measured as ,  
â€œOn a scale from 0 to 10, where 0 equals no pain and 10 equals the worst possible pain, what was the worst  pain in your operative knee in the last 24 hours ?â€ and  
â€œOn a scale from 0 to 10 , where 0 equals no pain and 10 equals the worst possible pain, 
what was the average  pain in your operative knee in the last 24 hours?â€ will be assessed:  
At 24 (Â±2 h), 48 (Â±2 h), 72 (Â±2 h), and 96 (Â±3 h) post- surgery .   
 
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  64 of 68 22 OCT 2021  18.2. Appendix 2: Subject â€™s Satisfaction  with Pain Management 
Questionnaire  
 
For the purposes of this study, only 1 question from the International Pain Outcome (IPO) 
Questionnaire ( Rothaug 2013) shall be used. Subject satisfaction will be recorded once 96 hours 
(Â±3 h) post-surgery.  
 Dear Sir/Madam,  
Please answer the following questions about your pain control after surgery Circle the one number that best shows how satisfied you are with the results of your pain treatment 
since your surgery: 
 
  

Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  65 of 68 22 OCT 2021  18.3. Appendix 3: Sensory Function Assessment (Light Touch  assessment ) 
(Cohort 1  Subjects) 
Pharmacodynamic assessments must be performed by blinded, trained, licensed medical staff 
(e.g., Physician, Registered Nurse, Physician Assistant) and documented on the Investigatorâ€™s study Delegation Log. A limited number of study staff (blinded to study drug assignment) should perform the sensory/motor assessments.  Sensory assessment for light touch will be performed at pre -dose (up to 15 min before block), 
15 min (Â±5 min), 30 min (Â±5 min), 45 min (Â±5 min), 1 h (Â±15 min), 2 h (Â±30 min), 8 h (Â±30 min), 12 h (Â±30 min), 24 h (Â±1 h), 30 h (Â±1 h), 48 h (Â±1 h), 60 h (Â±2 h), 72 h (Â±2 h), 84 h (Â±2 h), 96 h (Â±3 h), 120 h (Â±3 h), 144 h (Â±3 h), and 168 h (Â±3 h) from the end of the nerve block procedures, or until full sensory function has returned to baseline (pre -dose ) levels. Each light 
touch area of assessment will be rated independently. Additional unscheduled assessments may be performed, particularly  around the surgery, if no onset of block is noted on the last scheduled 
assessment prior to surgery.   For each sensory assessment performed, both locations mentioned below will be assessed for 
light touch. If on 168 h assessment there is a sensory deficit, the incident will be recorded as an AE. The physician will assess the subject for other etiologies that may explain the persistent sensory deficit. If the sensory deficit persists on 168 h, the subject is to return for unscheduled visit(s) at the Investigator's discretion until the sensory function has returned.  Sensory function assessment will include the following two locations:  
1. Proximal - Medial aspect of the lower leg (3 -4 cm below the knee)   
2. Distal - Medial aspect of the lower leg (3 -4 cm above ankle)  
 The intent of applying the tongue depressor to the contralateral leg is to establish a reference sensation to compare to the t est area. The subject is to determine if the sensation on the 
contralateral leg is the same as the test area (â€œYesâ€ = the same) or if there is a decreased sensation or not the same sensation (â€œNOâ€ = not the same).  The test may be repeated in case of ambig uous or inconsistent responses until the examiner is 
satisfied with the accuracy of the assessment. The assessments will be conducted single-blinded (i.e., the subject  will be instructed to close their eyes ). 
 After offset of sensory assessments are  noted ( return of light touch sensation in both test areas  
in a single assessment ), no subsequent assessments will be required. 
 Tongue Depressor Assessment  
The tongue depressor assessment procedures are as follows: 
â€¢ The subject will be instructed to close their eyes before the application of the wooden 
tongue depressor. 
â€¢ Instruct the subject you will be touching the subject on both legs and they will be asked if the touch sensation is the same (YES) or not the same (NO) when comparing each side. 
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  66 of 68 22 OCT 2021  â€¢ For the subjectâ€™s reference, the end of the tongue depressor is dragged over the 
contralateral assessment area with consistent light touch.  
â€¢ The end of the tongue depressor is then dragged over the corresponding test assessment area with consistent light touch. 
â€¢ The subject will be asked if the touch sensation of the tongue depressor is the same (YES) or not the same (NO) when comparing each side.  
â€¢ Record the subjectâ€™s response (YES or NO) to the touch sensation in the assessment 
area.  
â€¢ Proceed to test the other area as above.  
  
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  67 of 68 22 OCT 2021  18.4. Appendix 4: Motor Function Assessment  (Cohort 1  Subjects)  
Pharmacodynamic assessments must be performed by blinded, trained, licensed medical staff (e.g., 
Physician, Registered Nurse, Physician Assistant) and documented on the Investigatorâ€™s study 
Delegation Log. A limited number of study staff (blinded to study drug assignment) should perform the sensory/motor assessments. 
Motor function (onset and offset of motor block) will be assessed by active movement of the knee 
(knee extension). This will be used to determine the duration of the motor blockade. 
The motor function test will be performed at pre -dose (up to 15 min before block), 15 min (Â±5 min), 
30 min (Â±5 min), 45 min (Â±5 min), 1 h (Â±15 min), 2 h (Â±30 min), 8 h (Â±30 min), 12 h (Â±30 min), 24 
h (Â±1 h), 30 h (Â±1 h), 48 h (Â±1 h), 60 h (Â±2 h), 72 h (Â±2 h), 84 h (Â±2 h), 96 h (Â±3 h), 120 h (Â±3 h), 
144 h (Â±3 h), and 168 h (Â±3 h) from the end of the block procedures, or until motor function has 
returned to baseline (pre -dose) level . Once the offset  of motor block is recorded and documented, 
no further scheduled motor assessments are required.  
Additional unscheduled assessments may be performed, particularly around the surgery, if no onset 
of block is noted on the last scheduled assessment prior to surgery. 
If on 168 h assessment there is a motor function deficit, the incident will be recorded as an AE. The 
physician will assess the subject for other etiologies that may explain the persistent motor deficit. 
If the motor deficit persists on 168 h, the  subject is to return for unscheduled visit(s) at the 
Investigator's discretion until the motor function has returned. 
The motor block will be evaluated by performing Knee Extension. The following steps should be 
followed: 
1. Position the subject by sitting upright. 
2. Instruct the subject to straighten (extend) the knee. Avoid knee hyperextension. 
During post -operative period when the subject is unable to sit, knee extension will be tested with 
the bed in the chair position, or the head of the bed elevated as fa r as possible. Pillows will be placed 
under the knee to flex the hip to 90 degrees. The examiner assures that the foot is lifted off the bed when asking the patient to extend  the knee. 
 
The level of knee extension will be noted as either: 
Knee extension 
No knee extension  
  
Pacira Pharmaceuticals, Inc.   402-C- 335 (Adductor Canal  Block)  
EXPARELÂ®  Clinical Study Protoc ol Amendment 1  
 
   
CONFIDENTIAL  68 of 68 22 OCT 2021  18.5. Appendix 5: ASA Physical Status Classification System   
Last approved by the ASA House of Delegates on October 15, 2014 
 
ASA PS 
Classification  Definition  Examples, including, but not limited to:  
ASA I  A normal healthy patient  Healthy, non -smoking, no or minimal alcohol use  
ASA II  A patient with mild 
systemic disease  Mild diseases only without substantive functional 
limitations. Examples include (but not limited to): 
current smoker, social alcohol drinker, pregnancy, 
obesity (30 < BMI < 40), well -controlled 
DM/HTN, mild lung disease  
ASA III  A patient with severe 
systemic disease  Substantive functional limitations; One or more 
moderate to severe diseases. Examples include (but 
not limited to): poorly controlled DM or HTN, 
COPD, morbid obesity (BMI â‰¥40), active hepatitis, 
alcohol dependence or abuse, implanted 
pacemaker, moderate reduction of ejection 
fraction, ESRD undergoing regularly scheduled 
dialysis, premature infant PCA < 60 weeks, history 
(>3 mo nths) of MI, CVA, TIA, or CAD/stents.  
ASA IV  A patient with severe 
systemic disease that is a 
constant threat to life  Examples include (but not limited to): recent (< 3 
months) MI, CVA, TIA, or CAD/stents, ongoing 
cardiac ischemia or severe valve dysfunction, 
severe reduction of ejection fraction, sepsis, DIC, 
ARD or ESRD not undergoing regularly scheduled 
dialysis  
ASA V  A moribund patient who 
is not expected to survive 
without the operation  Examples include (but not limited to): ruptured 
abdominal/thoracic aneurysm, massive trauma, 
intracranial bleed with mass effect, ischemic bowel 
in the face of significant cardiac pathology or 
multiple organ/system dysfunction  
ASA VI  A declared brain -dead 
patient whose organs are 
being removed for donor 
purposes   
ARD=acute respiratory distress; ASA=American Society of Anesthesiologists; BMI=body mass index; 
CAD=coronary artery disease; COPD=chronic obstructive pulmonary disease; CVA=cerebrovascular accident; 
DIC=disseminated intravascular coagulation; DM=diabetes m ellitus; ESRD=end -stage renal disease; 
HTN=hypertension; MI=myocardial infarction; PCA=postconceptional age; PS=physical status; TIA=transient 
ischemic attack  
 